WO2021202245A1 - Régimes de traitement antiviral - Google Patents
Régimes de traitement antiviral Download PDFInfo
- Publication number
- WO2021202245A1 WO2021202245A1 PCT/US2021/024207 US2021024207W WO2021202245A1 WO 2021202245 A1 WO2021202245 A1 WO 2021202245A1 US 2021024207 W US2021024207 W US 2021024207W WO 2021202245 A1 WO2021202245 A1 WO 2021202245A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- subject
- virus
- acid
- nmn
- Prior art date
Links
- 230000003612 virological effect Effects 0.000 title description 10
- 238000011269 treatment regimen Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 348
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 179
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 133
- 229960003237 betaine Drugs 0.000 claims abstract description 100
- 239000012190 activator Substances 0.000 claims abstract description 97
- 238000000034 method Methods 0.000 claims abstract description 85
- 239000011701 zinc Substances 0.000 claims abstract description 70
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 70
- 235000016804 zinc Nutrition 0.000 claims abstract description 70
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims abstract description 67
- 230000008439 repair process Effects 0.000 claims abstract description 56
- -1 seine Chemical compound 0.000 claims abstract description 56
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 44
- 235000020956 nicotinamide riboside Nutrition 0.000 claims abstract description 43
- 239000011618 nicotinamide riboside Substances 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims abstract description 41
- 229930182817 methionine Natural products 0.000 claims abstract description 39
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 37
- LDHMAVIPBRSVRG-UHFFFAOYSA-O 1-methylnicotinamide Chemical compound C[N+]1=CC=CC(C(N)=O)=C1 LDHMAVIPBRSVRG-UHFFFAOYSA-O 0.000 claims abstract description 35
- 229940014144 folate Drugs 0.000 claims abstract description 35
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 35
- 235000019152 folic acid Nutrition 0.000 claims abstract description 35
- 239000011724 folic acid Substances 0.000 claims abstract description 35
- 229960001231 choline Drugs 0.000 claims abstract description 33
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims abstract description 33
- 230000032683 aging Effects 0.000 claims abstract description 32
- 229910052979 sodium sulfide Inorganic materials 0.000 claims abstract description 31
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 23
- 208000036142 Viral infection Diseases 0.000 claims abstract description 22
- 230000009385 viral infection Effects 0.000 claims abstract description 22
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 21
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 21
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims abstract description 21
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims abstract description 21
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 21
- 229940016667 resveratrol Drugs 0.000 claims abstract description 21
- 206010061218 Inflammation Diseases 0.000 claims abstract description 17
- 230000004054 inflammatory process Effects 0.000 claims abstract description 17
- 230000005779 cell damage Effects 0.000 claims abstract description 16
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 claims abstract 32
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract 22
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 claims abstract 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 180
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 80
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 claims description 74
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 72
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 72
- 229960001763 zinc sulfate Drugs 0.000 claims description 72
- PUEDDPCUCPRQNY-ZYUZMQFOSA-N D-ribosylnicotinate Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC(C([O-])=O)=C1 PUEDDPCUCPRQNY-ZYUZMQFOSA-N 0.000 claims description 65
- SENPVEZBRZQVST-HISDBWNOSA-N deamido-NAD zwitterion Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 SENPVEZBRZQVST-HISDBWNOSA-N 0.000 claims description 65
- TXGZJQLMVSIZEI-UQMAOPSPSA-N Bardoxolone Chemical compound C1=C(C#N)C(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5[C@H]4C(=O)C=C3[C@]21C TXGZJQLMVSIZEI-UQMAOPSPSA-N 0.000 claims description 60
- 239000002243 precursor Substances 0.000 claims description 57
- 230000006851 antioxidant defense Effects 0.000 claims description 52
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 45
- 229960004452 methionine Drugs 0.000 claims description 45
- 229940002612 prodrug Drugs 0.000 claims description 45
- 239000000651 prodrug Substances 0.000 claims description 45
- 241000282414 Homo sapiens Species 0.000 claims description 42
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 42
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims description 42
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 41
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 40
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 40
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 40
- 229950002483 bardoxolone Drugs 0.000 claims description 40
- AYMYWHCQALZEGT-ORCRQEGFSA-N butein Chemical compound OC1=CC(O)=CC=C1C(=O)\C=C\C1=CC=C(O)C(O)=C1 AYMYWHCQALZEGT-ORCRQEGFSA-N 0.000 claims description 40
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 40
- 235000012754 curcumin Nutrition 0.000 claims description 40
- 239000004148 curcumin Substances 0.000 claims description 40
- 229940109262 curcumin Drugs 0.000 claims description 40
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 40
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims description 40
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 40
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 40
- RAFHNDRXYHOLSH-SFTVRKLSSA-N eriodictyol 7-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C(C(=O)C[C@H](O2)C=3C=C(O)C(O)=CC=3)C2=C1 RAFHNDRXYHOLSH-SFTVRKLSSA-N 0.000 claims description 40
- 239000004250 tert-Butylhydroquinone Substances 0.000 claims description 40
- 235000019281 tert-butylhydroquinone Nutrition 0.000 claims description 40
- 241000700605 Viruses Species 0.000 claims description 39
- RQNVIKXOOKXAJQ-UHFFFAOYSA-N naphthazarin Chemical compound O=C1C=CC(=O)C2=C1C(O)=CC=C2O RQNVIKXOOKXAJQ-UHFFFAOYSA-N 0.000 claims description 38
- IZJDOKYDEWTZSO-UHFFFAOYSA-N phenethyl isothiocyanate Chemical compound S=C=NCCC1=CC=CC=C1 IZJDOKYDEWTZSO-UHFFFAOYSA-N 0.000 claims description 38
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 claims description 38
- JRYYVMDEUJQWRO-UHFFFAOYSA-N 2-methylnicotinamide Chemical compound CC1=NC=CC=C1C(N)=O JRYYVMDEUJQWRO-UHFFFAOYSA-N 0.000 claims description 34
- XVTDSQJAFPHQGF-UHFFFAOYSA-N 7h-purin-6-amine;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.NC1=NC=NC2=C1NC=N2 XVTDSQJAFPHQGF-UHFFFAOYSA-N 0.000 claims description 31
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 29
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 29
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 26
- 229960003105 metformin Drugs 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 25
- 229960004308 acetylcysteine Drugs 0.000 claims description 24
- AXFLRXAQPCLTEA-UHFFFAOYSA-N 2-phenyl-2-sulfanylidene-3h-1,3,2$l^{5}-benzoxazaphosphole Chemical compound N1C2=CC=CC=C2OP1(=S)C1=CC=CC=C1 AXFLRXAQPCLTEA-UHFFFAOYSA-N 0.000 claims description 23
- 229960005489 paracetamol Drugs 0.000 claims description 22
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 21
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims description 21
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 21
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 21
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 21
- 235000008434 ginseng Nutrition 0.000 claims description 21
- 235000005875 quercetin Nutrition 0.000 claims description 21
- 229960001285 quercetin Drugs 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 21
- 229960005559 sulforaphane Drugs 0.000 claims description 21
- 235000015487 sulforaphane Nutrition 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 20
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims description 20
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 20
- OQWKEEOHDMUXEO-UHFFFAOYSA-N (6)-shogaol Natural products CCCCCC=CC(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-UHFFFAOYSA-N 0.000 claims description 20
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 20
- UIXYUQXWIFEYBN-UHFFFAOYSA-N 1,4-diphenyltriazole Chemical class C1=C(C=2C=CC=CC=2)N=NN1C1=CC=CC=C1 UIXYUQXWIFEYBN-UHFFFAOYSA-N 0.000 claims description 20
- VHRUMKCAEVRUBK-GODQJPCRSA-N 15-deoxy-Delta(12,14)-prostaglandin J2 Chemical compound CCCCC\C=C\C=C1/[C@@H](C\C=C/CCCC(O)=O)C=CC1=O VHRUMKCAEVRUBK-GODQJPCRSA-N 0.000 claims description 20
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 20
- WPTTVJLTNAWYAO-KPOXMGGZSA-N Bardoxolone methyl Chemical compound C([C@@]12C)=C(C#N)C(=O)C(C)(C)[C@@H]1CC[C@]1(C)C2=CC(=O)[C@@H]2[C@@H]3CC(C)(C)CC[C@]3(C(=O)OC)CC[C@]21C WPTTVJLTNAWYAO-KPOXMGGZSA-N 0.000 claims description 20
- NYSZJNUIVUBQMM-BQYQJAHWSA-N Cardamonin Chemical compound COC1=CC(O)=CC(O)=C1C(=O)\C=C\C1=CC=CC=C1 NYSZJNUIVUBQMM-BQYQJAHWSA-N 0.000 claims description 20
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 claims description 20
- RAFHNDRXYHOLSH-UHFFFAOYSA-N Eriodictyol-7-beta-D-glucopyranosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C(C(=O)CC(O2)C=3C=C(O)C(O)=CC=3)C2=C1 RAFHNDRXYHOLSH-UHFFFAOYSA-N 0.000 claims description 20
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims description 20
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims description 20
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 20
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 20
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 20
- OQWKEEOHDMUXEO-BQYQJAHWSA-N [6]-Shogaol Chemical compound CCCCC\C=C\C(=O)CCC1=CC=C(O)C(OC)=C1 OQWKEEOHDMUXEO-BQYQJAHWSA-N 0.000 claims description 20
- 229930185474 acteoside Natural products 0.000 claims description 20
- FBSKJMQYURKNSU-ZLSOWSIRSA-N acteoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC(=O)\C=C\C=2C=C(O)C(O)=CC=2)[C@@H](CO)O[C@@H](OCCC=2C=C(O)C(O)=CC=2)[C@@H]1O FBSKJMQYURKNSU-ZLSOWSIRSA-N 0.000 claims description 20
- FBSKJMQYURKNSU-UKQWSTALSA-N acteoside I Natural products C[C@@H]1O[C@H](O[C@@H]2[C@@H](O)[C@H](OCCc3ccc(O)c(O)c3)O[C@H](CO)[C@H]2OC(=O)C=Cc4ccc(O)c(O)c4)[C@H](O)[C@H](O)[C@H]1O FBSKJMQYURKNSU-UKQWSTALSA-N 0.000 claims description 20
- NYSZJNUIVUBQMM-UHFFFAOYSA-N alpinetin chalcone Natural products COC1=CC(O)=CC(O)=C1C(=O)C=CC1=CC=CC=C1 NYSZJNUIVUBQMM-UHFFFAOYSA-N 0.000 claims description 20
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 claims description 20
- 235000008714 apigenin Nutrition 0.000 claims description 20
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 claims description 20
- 229940117893 apigenin Drugs 0.000 claims description 20
- 235000013793 astaxanthin Nutrition 0.000 claims description 20
- 239000001168 astaxanthin Substances 0.000 claims description 20
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 20
- 229940022405 astaxanthin Drugs 0.000 claims description 20
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 claims description 20
- 229960002873 benfotiamine Drugs 0.000 claims description 20
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 claims description 20
- 229940093265 berberine Drugs 0.000 claims description 20
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 claims description 20
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 claims description 20
- 229960001948 caffeine Drugs 0.000 claims description 20
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 20
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 20
- 235000005487 catechin Nutrition 0.000 claims description 20
- 229950001002 cianidanol Drugs 0.000 claims description 20
- 235000013985 cinnamic acid Nutrition 0.000 claims description 20
- 229930016911 cinnamic acid Natural products 0.000 claims description 20
- UBAXRAHSPKWNCX-UHFFFAOYSA-N diallyl trisulfide Chemical compound C=CCSSSCC=C UBAXRAHSPKWNCX-UHFFFAOYSA-N 0.000 claims description 20
- 229960004419 dimethyl fumarate Drugs 0.000 claims description 20
- 150000004141 diterpene derivatives Chemical class 0.000 claims description 20
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims description 20
- 235000012734 epicatechin Nutrition 0.000 claims description 20
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 20
- ATJVZXXHKSYELS-FNORWQNLSA-N ethyl (e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate Chemical compound CCOC(=O)\C=C\C1=CC=C(O)C(OC)=C1 ATJVZXXHKSYELS-FNORWQNLSA-N 0.000 claims description 20
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical class COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 20
- ATJVZXXHKSYELS-UHFFFAOYSA-N ferulic acid ethyl ester Natural products CCOC(=O)C=CC1=CC=C(O)C(OC)=C1 ATJVZXXHKSYELS-UHFFFAOYSA-N 0.000 claims description 20
- 229940045109 genistein Drugs 0.000 claims description 20
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 20
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 20
- OVSQVDMCBVZWGM-QCKGUQPXSA-N isoquercetin Natural products OC[C@@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@@H]1O OVSQVDMCBVZWGM-QCKGUQPXSA-N 0.000 claims description 20
- 150000004702 methyl esters Chemical class 0.000 claims description 20
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 claims description 20
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 claims description 20
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 claims description 20
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims description 20
- 229940121136 tecfidera Drugs 0.000 claims description 20
- 241001529453 unidentified herpesvirus Species 0.000 claims description 20
- QFRYQWYZSQDFOS-UHFFFAOYSA-N verbascoside Natural products CC1OC(COC2C(O)C(COC3OC(C(O)C(O)C3O)C(=O)O)OC(Oc4cc(O)cc5OC(=CC(=O)c45)c6ccc(O)c(O)c6)C2O)C(O)C(O)C1O QFRYQWYZSQDFOS-UHFFFAOYSA-N 0.000 claims description 20
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 claims description 19
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 claims description 19
- SWPKMTGYQGHLJS-RNVIBTMRSA-N (e)-3-[4-hydroxy-2-methoxy-5-[(2s)-3-methylbut-3-en-2-yl]phenyl]-1-(4-hydroxyphenyl)prop-2-en-1-one Chemical compound COC1=CC(O)=C([C@@H](C)C(C)=C)C=C1\C=C\C(=O)C1=CC=C(O)C=C1 SWPKMTGYQGHLJS-RNVIBTMRSA-N 0.000 claims description 19
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims description 19
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 claims description 19
- SWPKMTGYQGHLJS-AWEZNQCLSA-N Licochalcone E Natural products COc1cc(O)c(cc1C=CC(=O)c2ccc(O)cc2)[C@@H](C)C(=C)C SWPKMTGYQGHLJS-AWEZNQCLSA-N 0.000 claims description 19
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 19
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 19
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 claims description 19
- VABYUUZNAVQNPG-UHFFFAOYSA-N Piperlongumine Natural products COC1=C(OC)C(OC)=CC(C=CC(=O)N2C(C=CCC2)=O)=C1 VABYUUZNAVQNPG-UHFFFAOYSA-N 0.000 claims description 19
- WHAAPCGHVWVUEX-UHFFFAOYSA-N Piperlonguminine Natural products CC(C)CNC(=O)C=CC=CC1=CC=C2OCOC2=C1 WHAAPCGHVWVUEX-UHFFFAOYSA-N 0.000 claims description 19
- VABYUUZNAVQNPG-BQYQJAHWSA-N Piplartine Chemical compound COC1=C(OC)C(OC)=CC(\C=C\C(=O)N2C(C=CCC2)=O)=C1 VABYUUZNAVQNPG-BQYQJAHWSA-N 0.000 claims description 19
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 claims description 19
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 claims description 19
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 claims description 19
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 claims description 19
- 229960002297 fenofibrate Drugs 0.000 claims description 19
- 235000006539 genistein Nutrition 0.000 claims description 19
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 19
- 229960003987 melatonin Drugs 0.000 claims description 19
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 claims description 19
- 235000007625 naringenin Nutrition 0.000 claims description 19
- 229940117954 naringenin Drugs 0.000 claims description 19
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 19
- 235000014899 silybin Nutrition 0.000 claims description 19
- 229940043175 silybin Drugs 0.000 claims description 19
- 229930003802 tocotrienol Natural products 0.000 claims description 19
- 239000011731 tocotrienol Substances 0.000 claims description 19
- 229940068778 tocotrienols Drugs 0.000 claims description 19
- 235000019148 tocotrienols Nutrition 0.000 claims description 19
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 claims description 19
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 claims description 19
- 229960003048 vinblastine Drugs 0.000 claims description 19
- YAHHNSBXSDGEFB-UHFFFAOYSA-N 4-phenyl-1,2,4-triazole Chemical class C1=NN=CN1C1=CC=CC=C1 YAHHNSBXSDGEFB-UHFFFAOYSA-N 0.000 claims description 18
- QZPQTZZNNJUOLS-UHFFFAOYSA-N beta-lapachone Chemical compound C12=CC=CC=C2C(=O)C(=O)C2=C1OC(C)(C)CC2 QZPQTZZNNJUOLS-UHFFFAOYSA-N 0.000 claims description 18
- 239000004343 Calcium peroxide Substances 0.000 claims description 17
- LHJQIRIGXXHNLA-UHFFFAOYSA-N calcium peroxide Chemical compound [Ca+2].[O-][O-] LHJQIRIGXXHNLA-UHFFFAOYSA-N 0.000 claims description 17
- 235000019402 calcium peroxide Nutrition 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 17
- 241000709661 Enterovirus Species 0.000 claims description 16
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 16
- FBTSUTGMWBDAAC-UHFFFAOYSA-N 3,4-Dihydroxystyrene Chemical compound OC1=CC=C(C=C)C=C1O FBTSUTGMWBDAAC-UHFFFAOYSA-N 0.000 claims description 14
- 239000003550 marker Substances 0.000 claims description 14
- 241000700584 Simplexvirus Species 0.000 claims description 13
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 13
- 229940045999 vitamin b 12 Drugs 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000010521 absorption reaction Methods 0.000 claims description 11
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 10
- 229960001153 serine Drugs 0.000 claims description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 9
- 241000701806 Human papillomavirus Species 0.000 claims description 9
- 108090001005 Interleukin-6 Proteins 0.000 claims description 9
- 102000004889 Interleukin-6 Human genes 0.000 claims description 9
- 241001263478 Norovirus Species 0.000 claims description 9
- 241001115402 Ebolavirus Species 0.000 claims description 8
- 108700024827 HOC1 Proteins 0.000 claims description 8
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 8
- 241001502974 Human gammaherpesvirus 8 Species 0.000 claims description 8
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 8
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 8
- 241000702670 Rotavirus Species 0.000 claims description 8
- 101100178273 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HOC1 gene Proteins 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 208000005252 hepatitis A Diseases 0.000 claims description 8
- 150000002540 isothiocyanates Chemical class 0.000 claims description 8
- 235000004400 serine Nutrition 0.000 claims description 8
- 241000712461 unidentified influenza virus Species 0.000 claims description 8
- 241001302512 Banna virus Species 0.000 claims description 7
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 7
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 claims description 7
- 206010023927 Lassa fever Diseases 0.000 claims description 7
- 241001115401 Marburgvirus Species 0.000 claims description 7
- 241000712079 Measles morbillivirus Species 0.000 claims description 7
- 241000711386 Mumps virus Species 0.000 claims description 7
- 241001505332 Polyomavirus sp. Species 0.000 claims description 7
- 241000711798 Rabies lyssavirus Species 0.000 claims description 7
- 241000710799 Rubella virus Species 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- CUILPNURFADTPE-UHFFFAOYSA-N hypobromous acid Chemical compound BrO CUILPNURFADTPE-UHFFFAOYSA-N 0.000 claims description 7
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 claims description 7
- 235000009498 luteolin Nutrition 0.000 claims description 7
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 claims description 7
- 210000000716 merkel cell Anatomy 0.000 claims description 7
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 claims description 7
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 claims description 7
- 235000008209 xanthohumol Nutrition 0.000 claims description 7
- 241000725619 Dengue virus Species 0.000 claims description 6
- 241000702259 Orbivirus Species 0.000 claims description 6
- 241000150452 Orthohantavirus Species 0.000 claims description 6
- 241000315672 SARS coronavirus Species 0.000 claims description 6
- 241000710886 West Nile virus Species 0.000 claims description 6
- 241000907316 Zika virus Species 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 5
- 230000027288 circadian rhythm Effects 0.000 claims description 5
- 102100032752 C-reactive protein Human genes 0.000 claims description 4
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000007972 injectable composition Substances 0.000 claims description 4
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 3
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 claims description 3
- 208000007514 Herpes zoster Diseases 0.000 claims description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 230000002431 foraging effect Effects 0.000 claims description 3
- 229940100601 interleukin-6 Drugs 0.000 claims description 3
- 230000007067 DNA methylation Effects 0.000 claims description 2
- 208000001490 Dengue Diseases 0.000 claims description 2
- 206010012310 Dengue fever Diseases 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 208000005647 Mumps Diseases 0.000 claims description 2
- 206010037742 Rabies Diseases 0.000 claims description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 2
- 208000025729 dengue disease Diseases 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 2
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 2
- 208000010805 mumps infectious disease Diseases 0.000 claims description 2
- 201000005404 rubella Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 229940072251 zithromax Drugs 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims 4
- 241000208340 Araliaceae Species 0.000 claims 3
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000020329 Zika virus infectious disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 229930003779 Vitamin B12 Natural products 0.000 abstract description 38
- 235000019163 vitamin B12 Nutrition 0.000 abstract description 38
- 239000011715 vitamin B12 Substances 0.000 abstract description 38
- 239000003963 antioxidant agent Substances 0.000 abstract description 14
- 230000003078 antioxidant effect Effects 0.000 abstract description 13
- 235000006708 antioxidants Nutrition 0.000 abstract description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 abstract description 8
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 abstract description 7
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 abstract 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 abstract 1
- 229950006238 nadide Drugs 0.000 abstract 1
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 155
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 54
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 53
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 45
- 229960001570 ademetionine Drugs 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 42
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 38
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 37
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 37
- 102000011990 Sirtuin Human genes 0.000 description 33
- 108050002485 Sirtuin Proteins 0.000 description 33
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 30
- VDQVEACBQKUUSU-UHFFFAOYSA-M disodium;sulfanide Chemical compound [Na+].[Na+].[SH-] VDQVEACBQKUUSU-UHFFFAOYSA-M 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 25
- 102000004190 Enzymes Human genes 0.000 description 22
- 108090000790 Enzymes Proteins 0.000 description 22
- 238000009472 formulation Methods 0.000 description 20
- 240000004371 Panax ginseng Species 0.000 description 18
- 230000003647 oxidation Effects 0.000 description 17
- 238000007254 oxidation reaction Methods 0.000 description 17
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 14
- 150000000648 7,7',9,9'-tetra-cis-lycopenes Chemical class 0.000 description 14
- 240000002234 Allium sativum Species 0.000 description 14
- RUQCCAGSFPUGSZ-OBWQKADXSA-N Glucoraphanin Natural products C[S@](=O)CCCCC(=NS(=O)(=O)O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RUQCCAGSFPUGSZ-OBWQKADXSA-N 0.000 description 14
- GMMLNKINDDUDCF-JRWRFYLSSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1e)-5-[(r)-methylsulfinyl]-n-sulfooxypentanimidothioate Chemical compound C[S@@](=O)CCCC\C(=N/OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMMLNKINDDUDCF-JRWRFYLSSA-N 0.000 description 14
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 14
- 235000004611 garlic Nutrition 0.000 description 14
- 235000019136 lipoic acid Nutrition 0.000 description 14
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 13
- 230000001590 oxidative effect Effects 0.000 description 13
- 239000007800 oxidant agent Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 description 11
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 238000001994 activation Methods 0.000 description 11
- 230000008901 benefit Effects 0.000 description 11
- 235000004654 carnosol Nutrition 0.000 description 11
- 238000007069 methylation reaction Methods 0.000 description 11
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 10
- 210000000038 chest Anatomy 0.000 description 10
- 230000011987 methylation Effects 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 150000003573 thiols Chemical class 0.000 description 10
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 9
- 241000282412 Homo Species 0.000 description 9
- 229910002091 carbon monoxide Inorganic materials 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 230000009286 beneficial effect Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 108010088865 Nicotinamide N-Methyltransferase Proteins 0.000 description 7
- 102000009063 Nicotinamide N-methyltransferase Human genes 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 150000004053 quinones Chemical class 0.000 description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 description 7
- 208000025721 COVID-19 Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000007123 defense Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000005152 nicotinamide Nutrition 0.000 description 6
- 239000011570 nicotinamide Substances 0.000 description 6
- 229960003966 nicotinamide Drugs 0.000 description 6
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 108010065850 Tristetraprolin Proteins 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 231100000517 death Toxicity 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 102100031622 mRNA decay activator protein ZFP36 Human genes 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000031886 HIV Infections Diseases 0.000 description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 206010052015 cytokine release syndrome Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000003470 mitochondria Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- YZMHNNLDUWRZFW-UHFFFAOYSA-N (4-methoxyphenyl)-morpholin-4-yl-sulfanyl-sulfanylidene-$l^{5}-phosphane;morpholine Chemical compound C1COCC[NH2+]1.C1=CC(OC)=CC=C1P([S-])(=S)N1CCOCC1 YZMHNNLDUWRZFW-UHFFFAOYSA-N 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 3
- 102000007456 Peroxiredoxin Human genes 0.000 description 3
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 3
- 230000021736 acetylation Effects 0.000 description 3
- 238000006640 acetylation reaction Methods 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 150000001491 aromatic compounds Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000021615 conjugation Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000006196 drop Substances 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000005937 nuclear translocation Effects 0.000 description 3
- 108030002458 peroxiredoxin Proteins 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000010282 redox signaling Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- SNTWKPAKVQFCCF-UHFFFAOYSA-N 2,3-dihydro-1h-triazole Chemical class N1NC=CN1 SNTWKPAKVQFCCF-UHFFFAOYSA-N 0.000 description 2
- 102100021908 3-mercaptopyruvate sulfurtransferase Human genes 0.000 description 2
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
- IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 2
- KYLIZBIRMBGUOP-UHFFFAOYSA-N Anetholtrithion Chemical compound C1=CC(OC)=CC=C1C1=CC(=S)SS1 KYLIZBIRMBGUOP-UHFFFAOYSA-N 0.000 description 2
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 2
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 2
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 2
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 2
- 108010040163 CREB-Binding Protein Proteins 0.000 description 2
- 102100021975 CREB-binding protein Human genes 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102100034976 Cystathionine beta-synthase Human genes 0.000 description 2
- 108010073644 Cystathionine beta-synthase Proteins 0.000 description 2
- 102100035429 Cystathionine gamma-lyase Human genes 0.000 description 2
- 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 108010018924 Heme Oxygenase-1 Proteins 0.000 description 2
- 241000709721 Hepatovirus A Species 0.000 description 2
- 101000806846 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease Proteins 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- JUUBCHWRXWPFFH-UHFFFAOYSA-N Hydroxytyrosol Chemical compound OCCC1=CC=C(O)C(O)=C1 JUUBCHWRXWPFFH-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N N-phenylacetamide Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229960005238 anethole trithione Drugs 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 235000020934 caloric restriction Nutrition 0.000 description 2
- 235000020827 calorie restriction Nutrition 0.000 description 2
- 210000004323 caveolae Anatomy 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 108010022551 cysteine aminotransferase Proteins 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 231100000652 hormesis Toxicity 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 2
- 230000008263 repair mechanism Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- RLSBGGURBSZJLQ-SCGRZTRASA-N (2S)-2-amino-5-(diaminomethylideneamino)pentanoic acid zinc Chemical compound [Zn].N[C@@H](CCCN=C(N)N)C(O)=O.N[C@@H](CCCN=C(N)N)C(O)=O RLSBGGURBSZJLQ-SCGRZTRASA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- YCNMAPLPQYQJFC-UHFFFAOYSA-N (4-carbamothioylphenyl) 2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=CC2=CC(OC)=CC=C2C=C1C(C)C(=O)OC1=CC=C(C(N)=S)C=C1 YCNMAPLPQYQJFC-UHFFFAOYSA-N 0.000 description 1
- 150000005206 1,2-dihydroxybenzenes Chemical class 0.000 description 1
- 108030003918 3-mercaptopyruvate sulfurtransferases Proteins 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101100452003 Caenorhabditis elegans ape-1 gene Proteins 0.000 description 1
- 101100084165 Caenorhabditis elegans prdx-2 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 102100028908 Cullin-3 Human genes 0.000 description 1
- 101710094482 Cullin-3 Proteins 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- QWCNQXNAFCBLLV-IAGOWNOFSA-N Falcarindiol Natural products CCCCCCCC=C/[C@@H](O)C#CC#C[C@H](O)C=C QWCNQXNAFCBLLV-IAGOWNOFSA-N 0.000 description 1
- 108091007911 GSKs Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 102100032606 Heat shock factor protein 1 Human genes 0.000 description 1
- 102000002737 Heme Oxygenase-1 Human genes 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000753843 Homo sapiens 3-mercaptopyruvate sulfurtransferase Proteins 0.000 description 1
- 101000867525 Homo sapiens Heat shock factor protein 1 Proteins 0.000 description 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 description 1
- 101001112714 Homo sapiens NAD kinase Proteins 0.000 description 1
- 101001023770 Homo sapiens Transcription factor NF-E2 45 kDa subunit Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 108010050332 IQ motif containing GTPase activating protein 1 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 102000004034 Kelch-Like ECH-Associated Protein 1 Human genes 0.000 description 1
- 108090000484 Kelch-Like ECH-Associated Protein 1 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000007307 Maf Transcription Factors Human genes 0.000 description 1
- 108010033714 Maf Transcription Factors Proteins 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 101710167853 N-methyltransferase Proteins 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- 102100023515 NAD kinase Human genes 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 1
- 101710114687 Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 206010031096 Oropharyngeal cancer Diseases 0.000 description 1
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 description 1
- 102000017946 PGC-1 Human genes 0.000 description 1
- 108700038399 PGC-1 Proteins 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100020847 Protein FosB Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 241000921645 Ranunculus auricomus Species 0.000 description 1
- 102100034419 Ras GTPase-activating-like protein IQGAP1 Human genes 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 1
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 1
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 1
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 1
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 1
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 1
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- VDFOMVRWDSKWSL-UHFFFAOYSA-N Zerumbone Natural products CC1=C2CC(C)(C)C=C2C(=O)C(=CCC1)C VDFOMVRWDSKWSL-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- GWZOLWLJEJRQMZ-UHFFFAOYSA-N [S].S Chemical compound [S].S GWZOLWLJEJRQMZ-UHFFFAOYSA-N 0.000 description 1
- 229960001413 acetanilide Drugs 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000016520 artichoke thistle Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical compound SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical class OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000006706 cellular oxygen consumption Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000011280 coal tar Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 230000006203 ethylation Effects 0.000 description 1
- 238000006200 ethylation reaction Methods 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- QWCNQXNAFCBLLV-YWALDVPYSA-N falcarindiol Chemical compound CCCCCCC\C=C/[C@H](O)C#CC#C[C@H](O)C=C QWCNQXNAFCBLLV-YWALDVPYSA-N 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 235000003248 hydroxytyrosol Nutrition 0.000 description 1
- 229940095066 hydroxytyrosol Drugs 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000029226 lipidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 229950011347 mangafodipir trisodium Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 150000005480 nicotinamides Chemical class 0.000 description 1
- 201000006958 oropharynx cancer Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000005077 polysulfide Substances 0.000 description 1
- 229920001021 polysulfide Polymers 0.000 description 1
- 150000008117 polysulfides Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 230000000207 pro-atherogenic effect Effects 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000021738 protein deacetylation Effects 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical class OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940034379 riomet Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- BENFPBJLMUIGGD-UHFFFAOYSA-I trisodium;2-[2-[carboxylatomethyl-[[3-hydroxy-2-methyl-5-(phosphonatooxymethyl)pyridin-4-yl]methyl]amino]ethyl-[[3-hydroxy-5-[[hydroxy(oxido)phosphoryl]oxymethyl]-2-methylpyridin-4-yl]methyl]amino]acetate;manganese(2+) Chemical compound [H+].[H+].[H+].[Na+].[Na+].[Na+].[Mn+2].CC1=NC=C(COP([O-])([O-])=O)C(CN(CCN(CC([O-])=O)CC=2C(=C(C)N=CC=2COP([O-])([O-])=O)[O-])CC([O-])=O)=C1[O-] BENFPBJLMUIGGD-UHFFFAOYSA-I 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- GIHNTRQPEMKFKO-SKTNYSRSSA-N zerumbone Chemical compound C\C1=C/CC(C)(C)\C=C\C(=O)\C(C)=C\CC1 GIHNTRQPEMKFKO-SKTNYSRSSA-N 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 229940062776 zinc aspartate Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 229940071566 zinc glycinate Drugs 0.000 description 1
- 229940110280 zinc methionine Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- CNMFGFBWPBBGKX-SCGRZTRASA-L zinc;(2s)-2-amino-4-methylsulfanylbutanoate Chemical compound [Zn+2].CSCC[C@H](N)C([O-])=O.CSCC[C@H](N)C([O-])=O CNMFGFBWPBBGKX-SCGRZTRASA-L 0.000 description 1
- ROUREIAZUKQVBD-FHNDMYTFSA-L zinc;(2s)-2-amino-4-methylsulfanylbutanoate;hydrogen sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O.CSCC[C@H](N)C(O)=O ROUREIAZUKQVBD-FHNDMYTFSA-L 0.000 description 1
- POEVDIARYKIEGF-CEOVSRFSSA-L zinc;(2s)-2-aminobutanedioate;hydron Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O POEVDIARYKIEGF-CEOVSRFSSA-L 0.000 description 1
- LOUVRTYDLXWXRH-WOGKQDBSSA-L zinc;(e)-but-2-enedioate;hydron;hydrate Chemical compound [H+].[H+].O.[Zn+2].[O-]C(=O)\C=C\C([O-])=O.[O-]C(=O)\C=C\C([O-])=O LOUVRTYDLXWXRH-WOGKQDBSSA-L 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 description 1
- GIHNTRQPEMKFKO-UHFFFAOYSA-N zurembone Natural products CC1=CCC(C)(C)C=CC(=O)C(C)=CCC1 GIHNTRQPEMKFKO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the disclosed subject matter generally relates to compositions for defending against and repairing the effects of aging and for treating viral infections, e.g., COVID-19.
- Adverse effects of aging can be a result of accumulated unrepaired cellular damage.
- Accumulated damage to one’s immune system may reduce or prevent a patient’s ability to mount an effective immune response to pathogens, including viruses.
- New compositions and methods for repairing the effects of aging, including reversing accumulated cellular damage, and especially among cells of the immune system, are needed.
- the present disclosure provides methods and compositions for repairing the effects of aging, including reversing accumulated cellular damage, and especially among cells of the immune system. These methods and compositions are particularly useful in treating, preventing, and/or reducing the ill effects of a viral infection, e.g, resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- An aspect of the present disclosure is a composition for administering to a subject.
- the composition comprises: a repair system activator chosen from, nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, nicotinamide adenine dinucleotide (NAD+), nicotinamide riboside (NR), nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid riboside (NAR), 1- methylnicotinamide (MNM), cyclic adenosine monophosphate (cAMP), and any combination thereof; a methyl donor chosen from, betaine, S-5’-adenosyl-L-methionine (SAM), methionine, choline, serine, folate, vitamin B 12, and any combination thereof; and an antioxidant defense activator chosen from
- the repair system activator, the methyl donor, and the antioxidant defense activator are present in a combined amount of at least 5 wt.% of the composition.
- the repair system activator is nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, nicotinamide riboside (NR), or both.
- NMN nicotinamide mononucleotide
- NR nicotinamide riboside
- the methyl donor is betaine, methionine, or both.
- the antioxidant defense activator is Zinc (e.g., as zinc sulfate), calcium peroxide, N-Acetylcysteine, H2O2, H2S, orNaSH.
- the repair system activator, methyl donor, and antioxidant defense activator are in an amount sufficient to beneficially change a surrogate marker for aging level in a human when compared to the surrogate marker level prior to administration.
- the change in the level of the surrogate marker is lowered the surrogate marker is CMV IgG, C-Reactive Protein, Tumor Necrosis Factor-Alpha, or Interleukin-6.
- the change in the level of the surrogate marker is increased.
- the surrogate marker is DNA methylation.
- the composition further comprises water. In embodiments, the composition comprises at least 1 x 10 8 moles of the repair system activator, at least 1 x 10 8 moles of the methyl donor, and at least 1 x 10 9 moles of the antioxidant defense activator.
- the composition comprises nicotinamide mononucleotide (NMN) or the precursor or prodrug of NMN, Betaine, and zinc (e.g as zinc sulfate).
- the composition comprises NMN, Betaine, and Zinc Sulfate in a ratio of from about 7 and 20: to from about 4 and 10; to about 1.
- a unit dose of the composition comprises from about 0.8 grams and about 2.0 grams of NMN, from about 0.4 grams and 0.8 grams of Betaine, and from about 0.09 and 0.25 grams of Zinc Sulfate. In embodiments, the unit dose of the composition comprises from about 0.9 grams and about 1.1 grams of NMN, from about 0.45 grams and 0.55 grams of Betaine, and from about 0.1 and 0.12 grams of Zinc Sulfate. In embodiments, the unit dose of the composition comprises about 1 gram of NMN, 0.5 grams of Betaine, and about 0.11 grams of Zinc Sulfate.
- the composition further comprises from about 25 mg to about 100 mg of NaCl. In embodiments, the composition further comprises about 50 mg of NaCl.
- composition may be used in a method for reversing aging and/or for reversing accumulated cellular damage in a subject in need thereof.
- compositions may comprise or administered contemporaneously with Na+ (e.g., as NaCl) to increase the absorption of NMN or Betaine.
- Na+ e.g., as NaCl
- NNN Cocktail The herein described “unit dose”, “formulation”, and/or “composition” may be referred to as an “NMN Cocktail”.
- any herein-disclosed composition may be used in a method for treating, preventing, and/or reducing the ill effects of a viral infection in a subject in need thereof.
- the viral infection is caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); an enterovirus A-J; a rhinovirus A-C; a rotavirus A-C; a norovirus; an influenza virus A-C and their types such as H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, H7N9; a human papillomavirus; a polyomavirus: John Cunningham virus and Merkel cell virus; a poxvirus; a herpesvirus such as human simplex virus 1, human simplex virus 2, varicella zoster virus, Epstein-Barr virus or human herpesvirus 4; a human cytomegalovirus, Herpesvirus 6 (A
- an injectable formulation a tablet, a powder, and a beverage, each comprising any herein-disclosed composition.
- Another aspect of the present disclosure is a method for reducing inflammation in a subject in need thereof, for reversing aging and/or for reversing accumulated cellular damage in a subject in need thereof, and/or for treating, preventing, and/or reducing the ill effects of a viral infection in a subject in need thereof.
- the method comprising: administering to the subject any herein-disclosed composition.
- the composition is administered to a subject at a dosage of at least 1 x 10 6 moles /kg of the repair system activator to the subject, 1 x 10 6 moles /kg of the methyl donor to the subject, and 1 x 10 7 moles /kg of the antioxidant defense activator to the subject.
- the composition is injected over 8-12 days.
- the composition is in an aerosol, lyophilized, powder, or emulsion form.
- the subject in need thereof is a human.
- the composition is administered to the human for at least two months.
- the composition is in a tablet that is administered orally at least once daily.
- the composition further comprises water.
- the composition is administered to the subject once daily.
- the composition comprises nicotinamide mononucleotide (NMN) or the precursor or prodrug of NMN, Betaine, and Zinc ( e.g ., as zinc sulfate).
- the composition comprises Na+ (e.g., as NaCl) or is administered contemporaneously with Na+ (e.g, as NaCl) to increase the absorption of NMN or Betaine.
- the viral infection is caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); an enterovirus A-J; a rhinovirus A-C; a rotavirus A-C; a norovirus; an influenza virus A-C and their types such as H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, H7N9; a human papillomavirus; a polyomavirus: John Cunningham virus and Merkel cell virus; a poxvirus; a herpesvirus such as human simplex virus 1, human simplex virus 2, varicella zoster virus, Epstein-Barr virus or human herpesvirus 4; a human cytomegalovirus, Herpesvirus 6 (A&B), herpesvirus 7, and Kaposi's sarcoma-associated herpesvirus; a hepatitis A-E virus; Retroviruses like human
- the composition comprises NMN, Betaine, and Zinc Sulfate in a ratio of from about 7 and 20: to from about 4 and 10; to about 1.
- a unit dose of the composition comprises from about 0.8 grams and about 2.0 grams of NMN, from about 0.4 grams and 0.8 grams of Betaine, and from about 0.09 and 0.25 grams of Zinc Sulfate. In embodiments, the unit dose of the composition comprises from about 0.9 grams and about 1.1 grams of NMN, from about 0.45 grams and 0.55 grams of Betaine, and from about 0.1 and 0.12 grams of Zinc Sulfate. In embodiments, the unit dose of the composition comprises about 1 gram of NMN, 0.5 grams of Betaine, and about 0.11 grams of Zinc Sulfate.
- the unit dose further comprises from about 25 mg to about 100 mg of NaCl. In embodiments, the unit dose further comprises about 50 mg of NaCl.
- At least one unit of the composition is administered to the subject at each dosing. In embodiments, at least two units of the composition, at least three units of the composition, at least four units of the composition, or at least five units of the composition is administered to the subject at each dosing. In embodiments, the number of units of the composition per dosing relates in part to the weight of the subject. In embodiments, when a subject weighs 100 lbs or less, the subject is administered at least one unit of the composition per dosing and/or when a subject weighs over 100 lbs, the subject is administered at least one unit, at least two units, at least three units, or at least four units or at least five units of the composition per dosing. In embodiments, the subject receives at least one dosing per day, at least two dosings per day, at least three dosings per day, or at least four dosings per day.
- NNN Cocktail The herein described “unit dose”, “formulation”, and/or “composition” may be referred to as an “NMN Cocktail”.
- Yet another aspect of the present disclosure is a method for reducing inflammation in a subject in need thereof, for reversing aging and/or for reversing accumulated cellular damage in a subject in need thereof, and/or for treating, preventing, and/or reducing the ill effects of a viral infection in a subject in need thereof.
- a repair system activator chosen from nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, nicotinamide adenine dinucleotide (NAD+), nicotinamide riboside (NR), nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid riboside (NAR), 1- methylnicotinamide (MNM), cyclic adenosine monophosphate (cAMP), and any combination thereof; a methyl donor chosen from, betaine, S-5’-adenosyl-L-methionine (SAM), methionine, choline, serine, folate, vitamin B 12, and any combination thereof; and an antioxidant defense activator chosen from zinc (e.g ., as zinc sulfate, zinc (SAM), methionine
- the repair system activator, the methyl donor, and the antioxidant defense activator are administered at approximately the same time.
- the repair system activator is administered within 15, 30, 60, 90, or 120 minutes of the subject’s biological clock NAD+ peak. In embodiments, the repair system activator, the methyl donor, and the antioxidant defense activator are administered at different times.
- the subject is a human.
- the repair system activator, the methyl donor, and the antioxidant defense activator are administered to the human for at least two months.
- the repair system activator, the methyl donor, and the antioxidant defense activator are administered to the human once daily.
- Na+ e.g, as NaCl
- NMN or Betaine is administered to increase the absorption of NMN or Betaine.
- the viral infection is caused by a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); an enterovirus A-J; a rhinovirus A-C; a rotavirus A-C; a norovirus; an influenza virus A-C and their types such as H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, H7N9; a human papillomavirus; a polyomavirus: John Cunningham virus and Merkel cell virus; a poxvirus; a herpesvirus such as human simplex virus 1, human simplex virus 2, varicella zoster virus, Epstein-Barr virus or human herpesvirus 4; a human cytomegalovirus, Herpesvirus 6 (A&B), herpesvirus 7, and Kaposi's sarcoma-associated herpesvirus; a hepatitis A-E virus; Retroviruses like human
- the repair system activator, the methyl donor, and/or the antioxidant defense activator are each independently in the form of an injectable formulation, a tablet, a powder, and/or a beverage.
- the repair system activator, the methyl donor, and the antioxidant defense activator are respectively NMN, Betaine, and Zinc Sulfate and in a ratio of from about 7 and 20: to from about 4 and 10; to about 1.
- a unit dose of the repair system activator, the methyl donor, and the antioxidant defense activator comprises from about 0.8 grams and about 2.0 grams of NMN, from about 0.4 grams and 0.8 grams of Betaine, and from about 0.09 and 0.25 grams of Zinc Sulfate.
- the unit dose comprises from about 0.9 grams and about 1.1 grams of NMN, from about 0.45 grams and 0.55 grams of Betaine, and from about 0.1 and 0.12 grams of Zinc Sulfate.
- the unit dose comprises about 1 gram of NMN, 0.5 grams of Betaine, and about 0.11 grams of Zinc Sulfate.
- the unit dose further comprises from about 25 mg to about 100 mg of NaCl. In embodiments, the unit dose further comprises about 50 mg of NaCl.
- NNN Cocktail The herein described “unit dose”, “formulation”, and/or “composition” may be referred to as an “NMN Cocktail”.
- At least one unit of the repair system activator, the methyl donor, and the antioxidant defense activator is administered to the subject at each dosing.
- at least two units, at least three units, at least four units, or at least five units is administered to the subject at each dosing.
- the number of units per dosing relates in part to the weight of the subject.
- the subject receives at least one dosing per day, at least two dosings per day, at least three dosings per day, or at least four dosings per day.
- the subject is at least 50 years old.
- the subject has previously been treated with one or more of hydroxychloroquine, Zithromax, and zinc.
- the subject is administered the composition in accordance with the subject’s circadian rhythm.
- the subject is administered the composition to a substantially empty stomach.
- the present disclosure provides a composition
- a precursor or prodrug of nicotinamide mononucleotide (NMN) a methyl donor chosen from, betaine, S-5’-adenosyl-L-methionine (SAM), methionine, choline, serine, folate, vitamin B 12, and any combination thereof; and an antioxidant defense activator chosen from zinc (e.g as zinc sulfate), calcium peroxide, N- Acetyl cysteine, H 2 0 2 , H 2 S, NaSH, Na 2 S, ROS, RNS, RCS, RSOH, 0 2 ⁇ , OH ⁇ , x 0 2 , O3, HOC1, HOBr, HOI, ROOH, where R is alkyl, cycloalkyl, heteralkyl, heterocycloalkyl, alkenyl, heteroalkenyl, cycloalkenyl, or hetercycloalkenyl,
- NPN nic
- the composition comprises NMN, Betaine, and Zinc Sulfate in a ratio of from about 7 and 20: to from about 4 and 10; to about 1.
- a unit dose of the composition comprises from about 0.8 grams and about 2.0 grams of NMN, from about 0.4 grams and 0.8 grams of Betaine, and from about 0.09 and 0.25 grams of Zinc Sulfate. In embodiments, the unit dose of the composition comprises from about 0.9 grams and about 1.1 grams of NMN, from about 0.45 grams and 0.55 grams of Betaine, and from about 0.1 and 0.12 grams of Zinc Sulfate. In embodiments, the unit dose of the composition comprises about 1 gram of NMN, 0.5 grams of Betaine, and about 0.11 grams of Zinc Sulfate. In embodiments, the unit dose further comprises from about 25 mg to about 100 mg of NaCl. In embodiments, the unit dose further comprises about 50 mg of NaCl.
- NNN Cocktail The herein described “unit dose”, “formulation”, and/or “composition” may be referred to as an “NMN Cocktail”.
- Another aspect is a disposable waterproof and/or air proof container comprising any herein-disclosed composition.
- the disposable waterproof and/or air proof container comprises instructions for use.
- kits comprising at least ten of the disposable waterproof and/or air proof containers.
- FIG. 1 is a schematic showing effects of lowered NAD+, SAM and Nrf2, which occurs as cells age. Proposed mechanisms for reversing aging and treating viral infections are shown.
- the three components NMN, Betaine, and H2O2 are used as illustrative of the methods and compositions for reversing aging. Other components used in the methods and compositions of the present disclosure would likewise reverse aging.
- FIG. 2 is a table showing patient characteristics for patients described in Example 1.
- FIG. 3 is a table showing pre-treatment clinical conditions for patients described in Example 1.
- FIG. 4 is a table showing patient outcomes for patients described in Example 1.
- FIG. 5 to FIG. 9 are chest x-rays for Patient 1 described in Example 1.
- FIG. 10 is a table showing vital signs of Patient 1 described in Example 1.
- FIG. 11 is a table showing vital signs of Patient 2 described in Example 1.
- FIG. 12 is a table showing vital signs of Patient 3 described in Example 1.
- FIG. 13 to FIG. 16 are chest x-rays for Patient 4 described in Example 1.
- FIG. 17 is a table showing vital signs of Patient 4 described in Example 1.
- FIG. 18 and FIG. 19 are chest x-rays for Patient 5 described in Example 1.
- FIG. 20 is a table showing vital signs of Patient 5 described in Example 1.
- FIG. 21 is a chest x-ray for Patient 6 described in Example 1.
- FIG. 22 is a table showing vital signs of Patient 6 described in Example 1.
- FIG. 23 is a chest x-ray for Patient 6 described in Example 1.
- FIG. 24 is a chest x-rays for Patient 7 described in Example 1.
- FIG. 25 is a table showing vital signs of Patient 7 described in Example 1.
- FIG. 26 to FIG. 28 are chest x-rays for Patient 7 described in Example 1.
- FIG. 29 is a chest x-rays for Patient 8 described in Example 1.
- FIG. 30 is a table showing vital signs of Patient 8 described in Example 1.
- FIG. 31 is a chest x-rays for Patient 8 described in Example 1.
- FIG. 32 to FIG. 35 are chest x-rays for Patient 10 described in Example 1.
- FIG. 36 is a table showing vital signs of Patient 10 described in Example 1.
- compositions are particularly useful in reversing cellular consequences of aging and in treating, preventing, and/or reducing the ill effects of a viral infection, e.g., resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- NADH is not used by sirtuins enzymes and is only inhibitory at concentrations far greater that those predicted for cells. NADH is also not used for generation of NADP+ by the cytosolic NADK enzyme and this generated NADP+ is rapidly turned into NADPH.
- Caloric restriction induces a “nutritional stress” that results in a depletion of the cells energy stores (ATP, NADH, etc.). The “depleted energy forms” of this stored energy are cAMP and NAD+.
- NAD+ activates a set of enzymes called Sirtuins as well as PARPs.
- Sirtuins As well as PARPs.
- What the data disclosed herein shows is that by providing NAD+ or compounds or compositions having a similar activity, immune system markers are reduced, which has been shown to be associated with anti-aging. These data are consistent with an increased activation of Sirtuins, through interaction with NAD+, or similar acting molecules.
- the positive effect of NAD+ can level off, presumably because of other reactions taking place in the organism, including in the active site of the Sirtuins themselves.
- compositions and formulations which contain three categories of compositions, or methods where three different categories of molecules are administered, alone, in conjunction, or in combination to a subject.
- NAD+ should be available to turn on and be used by Sirtuins
- methyl donors should be available to methylate DNA and other entities needing methylation like the reaction of nicotinamide to 1-methylnicotinamide by the nicotinamide-N-methyltransferase (NNMT) enzyme, and
- a reducing balance should be provided so that important enzymes, such as Sirtuins, can have the thiol (sulfur) groups in their reactive sites maintained in a reduced state.
- compositions, formulations, and methods that reduce markers of inflammation related to aging and are consistent with enhancing these three goals.
- one provides enough oxidation from H2O2 to provide pre conditioning from signaling to turn on the anti-oxidant defense and repair system but not enough to create oxidized damage like oxidizing the thiol groups in the Sirtuin active site that turns the Sirtuin enzymes activities off.
- the APE-1/ Ref-1 is a molecule that protects the thiol groups of amino acids in the Sirtuin active site from oxidation by H2O2. This can be kept active.
- Nrf2 nicotinamide-N-methyltransf erase
- compositions, formulations, and methods which turn on, enhance, and in some formulations keep on, the human defense and repair mechanisms involving the Sirtuin enzymes.
- These compounds, compositions and formulations comprise one or more items from each of three (3) categories alone or in combination, and can be administered through ingestion, injection, inhalation, application to the skin, or any other means.
- the disclosed compounds, compositions, and formulations can perform at least one of the following activities: Protect against further cellular damage from the aging process; Repair cellular damage from the aging process; Delay the onset of the diseases of aging where aging is a causal factor; Promote weight loss / reduce hunger; and Promote more productive sleep, waking more rested.
- Diseases of aging include inflammation, heart disease (including heart attack and heart failure), stroke, neurodegenerative disease such as Alzheimer’s disease, diabetes, cancer, respiratory disease, systemic autoimmune disease (including arthritis) and muscle wasting.
- the herein-disclosed methods and compositions are particularly useful in treating, preventing, and/or reducing the ill effects of a viral infection, e.g., resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Death from viral attacks correlates to the speed of activation of CD-8 T-Cells.
- a viral infection e.g., resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- Death from viral attacks correlates to the speed of activation of CD-8 T-Cells.
- the late rise of 11-6 in a “cytokine storm” may be due to this late start, since with early start IL-6 does not seem to have the late rise.
- CD-8 T-cells with high CD38 expression have decreased cytotoxic capacity and higher rates of infections and increased propensity for infections.
- the late rise of 11-6 may be due to the low ability of the T-Cells to kill viruses.
- CD-8 T-Cells Activation of CD-8 T-Cells needs CD38 and CD-38 not only is correlated to the Adaptive Immune system CD-8 T-Cells but also the Innate Immune system Toll-like Receptors.
- CD-38 Other correlations of CD-38 include:
- NF-kB oxidation; CD-38 active; inflammation is increased; decreased methylation (like H3K9me3 & H3K27me3); increased LINE-1; and increased II- 6 gene transcription.
- Nrf2 reduction; CD-38 inactive; increased methylation; endogenous (LINE-1) viruses are inactivated.
- TNF-a modulates immune response to viral attack; an inducer of CD-38; CD- 38 has a TNF receptor; lowered by compositions and methods disclosed in below working examples.
- IL-6 modulates immune response to viral attack; lowered by compositions and methods disclosed in below working examples; reduction of LINE-1 leads to reduction of 11-6; basal level correlates to favorable health-span and life-span.
- NAD+ CD-38 rapidly degrades NAD+ and NMN its precursor; when CD-38 is active, NAD+ is less available to Sirtuins and Defense and Repair.
- Tristetraprolin induced by CD-38 in the onset of acute inflammation; TTP-dependent degradation of CD-38 activates Sirtuin-1 at the onset of resolution; TTP controls the resolution of inflammation; Carbon monoxide (CO) inhibits inflammation by increasing TTP expression; a Phase 1 clinical trial with low dose inhaled carbon monoxide in (sepsis-induced) ARDS was successfully conducted showing it was feasible to give precise administration of CO, CO was well-tolerated and that CO was safe.
- CO Carbon monoxide
- Zinc (+2) inhibits Coronavirus RNA-synthesizing machinery and impairs a number of RNA viruses
- Zinc (+2) is important in regulating the immune system.
- zinc may be of benefit or harm due to its correlation to its turning on Nrf2 which correlates to the turning off of NF-kB (and vice versa) which at certain stages of certain viral replication can be of benefit.
- zinc is provided as zinc acetate, zinc arginate, zinc aspartate, zinc chloride, zinc citrate, zinc difumarate hydrate, zinc gluconate, zinc glycinate, zinc methionine, zinc monomethionine, zinc muratab, zinc orotate picolinate, zinc oxide, zinc pyrithione, or zinc sulfate.
- zinc is provided as zinc sulfate.
- a unit dose of zinc comprises about 25 mg of zinc.
- a patient experiencing a “cytokine storm syndrome” and the overwhelming oxidation and inflammation involved will lead to an active CD-38 that breaks down all NAD+ and its precursor NMN very rapidly.
- levels of NAD+ via the methods and compositions of the present disclosure
- the methods and compositions of the present disclosure are particularly useful in treating, preventing, and/or reducing the ill effects of a viral infection, e.g., resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- the methods of the present disclosure include administering a composition in adherence to the Circadian rhythm. Without wishing to be bound by theory, such adherence makes for a better therapeutic outcome, especially against viral attacks, e.g., by SARS-CoV-2.
- An advantage of the methods and compositions of the present disclosure is that they can provide a therapy against a viral attack (e.g, by SARS-CoV-2) in patients who cannot receive standard treatments, e.g, IL6 blockers or Remdesivir, due to sensitivity or allergy or adverse interactions with other therapies.
- a viral attack e.g, by SARS-CoV-2
- standard treatments e.g, IL6 blockers or Remdesivir
- Illustrative viral infections may be caused by one or more of enteroviruses A-J; rhinoviruses A-C; rotaviruses A-C; norovirus; influenza virus A-C and their several types like H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, H7N9, and their other relatives; human papillomaviruses (HPV); polyomaviruses like John Cunningham virus (JCV) and Merkel cell virus (MCV); poxviruses; herpesviruses such as human simplex virus 1 (HSV- 1), human simplex virus 2 (HSV-2), varicella zoster virus, Epstein-Barr virus (human herpesvirus 4; EBV/HHV-4), human cytomegalovirus (HHV-5), Herpesvirus 6 (A&B), herpesvirus 7, and Kaposi's sarcoma-associated herpesvirus
- Non-cancer diseases include (i) non-cancer diseases: enteritis (enteroviruses A-J); common cold (rhinoviruses A-C); gastroenteritis, diarrhoea (rotaviruses A-E, norovirus); gastroenteritis (norovirus); influenza (influenza virus A-C); progressive multifocal leukoencephalopathy (JCV), nephrophathy, Merkel cell cancer (MCV), smallpox (variola) (poxvirus); herpes (HSV-1, HSV-2); chicken-pox, herpes zoster (shingles) (varicella zoster virus); infectious mononucleosis (HHV-4); hepatitis A (hepatitis A virus); hepatitis B (hepatitis B virus); hepatitis C (hepatitis C virus); acquired immunodeficiency syndrome (HIV-1, HIV-2, and their subtypes); severe acute respiratory infections
- Category 1 which are Repair System Activators
- Category 2 which are Methyl Donors
- Category 3 which are Antioxidant Defense Activators
- compositions comprising a first compound, a second compound, and a third compound
- the first compound comprises nicotinamide adenine dinucleotide (NAD+), NAD+ precursor such as nicotinamide mononucleotide (NMN), a precursor or prodrug of NMN, nicotinamide riboside (NR), nicotinic acid riboside (NAR), nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), analog of NAD+ that promotes NAD+ use such as 1-methylnicotinamide (MNM), cyclic adenosine monophosphate (cAMP)
- the second compound comprises S-5’-adenosyl-L- methionine (SAM), SAM precursor such as methionine, betaine, choline, serine, folate, vitamin B12,
- compositions wherein the first compound, comprises NAD+ NMN, NR, NaMN, NaAD, NAR, MNM, cAMP, alone or in combination. Also disclosed are compositions wherein the first compound comprises NMN. Also disclosed are compositions wherein the first compound comprises a precursor or prodrug of NMN, e.g., a compound that increases NMN production in the body.
- compositions wherein the composition lowers a Surrogate Marker for Aging are also disclosed.
- the surrogate marker is CMV IgG, C- Reactive Protein, Tumor Necrosis Factor-alpha, or Interleukin-6 Serum.
- Na e.g, via NaCl
- compositions wherein the composition is formulated for injection are also disclosed.
- compositions wherein the composition is in tablet form or aerosol are also disclosed.
- compositions wherein the composition comprises at least 1 x 10 8 moles of the first compound, at least 1 x 10 8 moles of the second compound, and at least 1 x 10 9 moles of the third compound.
- NNN Cocktail The herein described “unit dose”, “formulation”, and/or “composition” may be referred to as an “NMN Cocktail”.
- Sirtuins require NAD+.
- Providing a repair system activator can turn on the Sirtuins.
- Examples of a repair system activator include NAD+, NAD+ precursor such as NMN, NR, NaMN, NaAD, NAR, analog of NAD+ that promotes NAD+ use such as MNM, and cAMP, or any combination thereof.
- a preferred repair system activator is the NAD+ precursor NMN (to make NAD+, to turn on, and be consumed by Sirtuins, which provides the benefit from Calorie Restriction).
- NAD+ typically naturally peaks in the morning and the evening such as at 8 AM and 8 PM, and thus the addition of NAD+ or precursor that would turn into NAD+ would be added, for example, preferentially in the 7 AM to 8 AM and the 7 PM to 8 PM time frame.
- Typical formulations provide greater or equal to 1.19 x 10 4 moles/kg-of-subject NMN, NAD+, or NAD+ precursor when administered (NMN is 334.22 grams / mole).
- a preferred repair system activator is a precursor or prodrug of NMN, e.g, a compound that increases NMN production in the body.
- NAD+ and NR are less preferred because NAD+ is not absorbed well through the digestive system and the enzymes that make NMN from NR are not found in every cell of the body.
- Orally delivered NR has also been shown to largely not reach muscle.
- NMN neurotinamide mononucleotide
- the dosage can be adjusted for absorption and Na (e.g via NaCl) can be added for active transport absorption. It is preferred to administer the Repair System Activator such as NMN, through water and drinking. A precursor or prodrug of NMN can also be administered, in further examples.
- repair system activators are administered for reducing inflammation markers related to aging.
- repair system activators are any compound, composition, formulation, molecule, biologic, or substance, which activates sirtuin enzymes. These types of enzymes prefer a redox balance near or at reducing to be optimized. Examples of such molecules that activate Sirtuin are NAD+, NAD+ precursor such as NMN, NR, NaMN, NaAD, NAR, analog of NAD+ that promotes NAD+ use such as MNM, and cAMP.
- SAM adenosyl-L-methionine
- SAM can provide the methyl group for nicotinamide, which has aging properties by stopping Sirtuin enzymes from working. This methylation of nicotinamide occurs via N-methyltransferase (NNMT) N-m ethylation to 1- methylnicotinamide.
- This nicotinamide with a methyl group attached provides competition to the available nicotinamide molecules that can get into the Sirtuin enzyme and decrease the Sirtuin enzyme’s reactive ability; thus, preventing this process from happening in proportion to the concentration of each of the two competitors.
- the timing for giving would be with the Repair System Activator, such as NAD+ or NAD+ precursor.
- SAM also provides the methyl groups to reduce the hypo-methylation seen in aging and in the right context it can to be used beneficially to combat aging, example: the need for H3K4me3 methylation of DNA found especially in older people.
- Methyl Donors in addition to betaine, which can be used include SAM, methionine, choline, serine, folate, and B 12. Typically, these alternatives are less preferred because only about 2% of SAM get into the body when ingested; choline needs extra NAD+ to be made into betaine, which is in short supply in the body.
- Serine helps make SAM from Methionine in two ways.
- This dose can be given over 24 hours and can be divided into two approximately equal doses taken approximately 12 hours apart.
- the dose can be dissolved in water and drunk by the subject.
- the administration can be along with the administration of the category 1 compound or composition.
- the methylation donors are administered to a subject, and these methylation donors are molecules, substances, compositions, compounds, and formulations, which increase the methylation of molecules or methylate molecules themselves.
- methyl donors prefer a Redox balance to be near reduction for optimal activity.
- S-5’Adenosyl -L- methionine (SAM) precursors include methionine, betaine, choline (a precursor of betaine), serine, folate, Vitamin B12 alone or in combination.
- the antioxidant defense When providing a category 3 compound, composition, or formulation the antioxidant defense is turned on. Having the antioxidant defense enzymes working increases the reduction of the thiol (sulfur) groups in the reactive site of Sirtuin enzymes and others with similar regulation. This prevents the Sirtuin enzymes from turning off due to thiol oxidation.
- One way to create a generally reducing environment is to “shock” the organism by a pulsed burst of oxidants, such as H2O2.
- oxidants such as H2O2.
- H2O2 oxidants
- pre-conditioning with oxidants to shock on the system, and one keeps them on by additional timed shock pulses of oxidants prior to the antioxidant enzymes turning off due to their feedback loops that turn them off or down when they are not challenged by oxidants.
- the pulse of oxidants for the preconditioning one uses a sufficient level of oxidants to turn on and keep on the antioxidant enzymes.
- H2O2 hydrogen peroxide
- H 2 O 2 can oxidize thiol groups on proteins / enzymes thereby changing their enzymatic properties.
- This pre-conditioning low level oxidation by H 2 O 2 can be given in a pulsed, time controlled, and dose-controlled fashion to turn on enzymes and processes without providing oxidation in excess of what is needed to turn on enzymes including anti-oxidant defense and repair systems enzymes, because excess oxidation causes cellular damage and harm.
- Any small molecule (non-enzyme) antioxidants should be taken at other time periods (other than the time period of the oxidative pulse) so as not to diminish this temporal effect of the oxidative pulse.
- Hydrogen peroxide (H 2 O 2 ) is a ubiquitous oxidant present in all aerobic organisms. H 2 O 2 is now appreciated as a messenger molecule and it provides sensitivity to redox signaling. H 2 O 2 provides oxidative modification of amino acid side chains in proteins; in decreasing order of reactivity and biological reversibility, cysteine, methionine, proline, histidine and tryptophan. Thiol modification is key in H 2 O 2 sensing and perception in proteins. Hydrogen peroxide has been found to mimic insulin activity, elicit arterial pulmonary relaxation, stimulate cell proliferation, and activate NF-KB and AP-1. The functional consequences of H 2 O 2 signaling concern fundamental biological processes.
- H 2 O 2 With recognition of the role of low-level oxidants stimuli for altering the set point of gene expression for batteries of enzymes, known as Hormesis.
- Transcriptional factors effected by H 2 O 2 include AP-1, Nrf2, CREB, HSF1, HIF-1, TPSS, NF-KB, NOTCH, SP1, and SCREB- 1 most involved in regulation of cell damage response, cell proliferation (cell cycle regulation) differentiation and apoptosis.
- Protein acetylation is regulated by H 2 O 2. Protein deacetylation is regulated by Sirtuins. H 2 O 2 increase acetylation and Sirtuins decrease acetylation, so H 2 O 2 and Sirtuins effects are in pushing acetylation reaction pathways in the opposite directions.
- Sirtl is very sensitive to H 2 O 2 inhibition of 1 pmol of extracellular H 2 O 2.
- Sirtl is protected by thiol oxidation from (APE1 / Ref-1). It governs the redox state and activity of Sirtl. It reduces the thiol groups in the active site of Sirtl, H 2 O 2 oxidizes the thiols in Sirtl’ s active site.
- Sirtl is also regulated by redox-dependent phosphorylation. Need for pulsing of signaling oxidants
- H 2 O 2 High levels of H 2 O 2 increase defenses by preconditioning and thus can ultimately protect against increase of oxidized thiols in Sirtuin’s active site and Sirtl’s decrease in activity by an oxidative challenge.
- Adaptation to H 2 O 2 decrease H 2 O 2 permeability of plasma membranes. Different cell membranes have a full range of permeability to H 2 O 2.
- Aquaporins also regulate H 2 O 2 transport across bio-membranes.
- Metformin the most widely prescribed antidiabetic drug in the world, increases hydrogen peroxide (H 2 O 2 ); this upregulates peroxiredoxin-2 (PRDX-2). Metformin increases lifespan in C. elegans and taking away the PRDX-2 gene takes away this effect. PRDX-2 appears to have the role of translating oxidative stress into a downstream pro longevity signal. Treatment with N-acetylcysteine (NAC) and butylated hydroxyanisole (BHA), which are small molecule antioxidants, abolished the positive effect of metformin on lifespan. Pharmaceuticals that increase hydrogen peroxide in the body can also be used for this category either in addition to H 2 O 2 or as a substitute for adding hydrogen peroxide itself. Pharmaceuticals that increase H 2 O 2 in the body include metformin and acetaminophen.
- H 2 O 2 in the body need also to be included in the calculation of the oxidative pulse given in category #3.
- An example is Acetaminophen (the ingredient in Tylenol), which is a pharmaceutical that is known to increase H 2 O 2 in the body.
- N-acetyl-l-cysteine (NAC) is a compound that is known to counter many effects of H 2 O 2 in the body.
- the APE-1/ Ref-1 is a molecule that protects the thiol groups of the Sirtuin enzymes, which should remain active.
- the same or similar process for the nicotinamide-N-methyltransferase (NNMT) enzyme is theorized.
- H 2 O 2 hydrogen peroxide
- approximately 100 mM concentration of food grade (commercial grade has acetanilide in it as a stabilizer) H 2 O 2 in the 400 to 500 mL of water per individual dose is preferred, which can be taken alone or with Category 1 and Category 2 compounds or compositions.
- one drop of H2O2 is 0.05 mL.
- a preferred method of administration is to ingest H2O2 by dissolving H2O2 in deionized / distilled water and drinking.
- a preferred timing of dosage concentration, time taken and length of time taking is to use the same timing as #1 and #2 when in water.
- H2O2 is partially enhanced from endurance exercise do exercise directly before or after.
- metformin can come in liquid form, Riomet, as well as tablets.
- liquid form 5 mL is equal to a 500 mg tablet. It reaches peak plasma concentrations in 1 to 3 hours in immediate release form and a steady state in one to two days. It is typically 50 to 60% bioavailable under fasting conditions. One would need to use this data to time and dose appropriately with Metformin.
- Calcium peroxide turns into hydrogen peroxide when in water.
- An advantage of using this compound is that it exists as a solid and can be combined with other dry compounds useful in compositions of the present disclosure.
- a composition may be stored, shipped, and/or provided in a product sachet.
- H2O2 can be replaced with calcium peroxide.
- Hydrogen Sulfide (H2S) Hydrogen Sulfide
- H2S hydrogen peroxide
- NaSH a H2S donor
- H2O2 hydrogen sulfide
- Plasma H2S levels decrease in humans over 50 to 80 years of age and plasma levels of 3 ⁇ 4S in patients with cardiovascular disease (CHD) show a significant inverse correlation with severity of CHD and changes in the coronary artery.
- NaSH decreases ROS and enhances SOD, GPx and GST expression.
- Exogenous 3 ⁇ 4S has a protective effect on maintaining the circadian rhythm of clock genes by changing the NAD+/NADH ratio and enhancing the Sirtl protein.
- H2S is also an important endogenous inhibitor of key elements of acute inflammatory reactions by down regulating NF-kB or upregulating heme oxygenase 1 expression.
- 3 ⁇ 4S can activate ATP-sensitive, intermediate-conductance and small-conductance potassium channels through cysteine S-sulfhydration causing endothelial and smooth muscle cell hyperpolarization which intern causes vasorelaxation of vascular endothelium and lowering of blood pressure.
- 3 ⁇ 4S has a direct inhibitory effect on angiotensin-converting enzyme (ACE) activity.
- ACE angiotensin-converting enzyme
- NaSH increases the expression of eNOS and PGC-1 Alpha, which both play a role in mitochondria biogenesis and function.
- 3 ⁇ 4S upregulates the MAPK pathway. It has been inferred that calorie restriction may help maintain 3 ⁇ 4S signaling.
- GYY4237 a slow releasing 3 ⁇ 4S donor can kill seven different human cancer cell lines in a concentration- dependent manner.
- Sulforaphane also a 3 ⁇ 4S donor, has dose-dependent antiprostate cancer (PC-3) properties.
- H2S is a gasotransmitter. Gasotransmitters are endogenously produced at low levels and are able to freely diffuse through cell membranes to invoke cellular signaling. The three gasotransmitters are nitric oxide (NO), carbon monoxide (CO), and hydrogen sulfide (H2S).
- NO nitric oxide
- CO carbon monoxide
- H2S hydrogen sulfide
- Hydrogen sulfide is synthesized from L-cysteine.
- Cystathionine gamma-lyase CSE
- cystathionine beta-synthase CBS
- cysteine aminotransferase CAT
- 3- mercaptopyruvate sulfurtransferase MST
- H2S 3- mercaptopyruvate sulfurtransferase
- 3 ⁇ 4S regulates lipid peroxidation and antioxidant enzyme (GPx, T- SOD, Cu/Zn-SOD, and Mn-SOD) activities in the liver, by administration of 3 ⁇ 4S donor NaSH to the mice by injection of 0.05 mM of NaSH / kg body weight / day dissolved in 10 mL / kg body weight saline.
- Mitochondria are able to use ThS under hypoxia and stress conditions to produce ATP.
- ThS antioxidant ability
- ThS can scavenge superoxide and ThS can upregulate glutathione.
- ThS has been shown to activate Nuclear factor-erythroid 2-related factor 2 (Nfr2), which turns on antioxidant genes.
- Na?S for 7 days increased Nrf2 expression in both cytosolic and nuclear fractions.
- Nrf2 which up regulates expression of antioxidant response element-regulated genes, is upregulated by ThS.
- ThS activation causes Nrf2 to separate itself from its adherent inhibitor, Kelch-like ECH- associated protein 1 in the cytosol then translocate to the nucleus and bind to a specific enhancer sequence, known as the antioxidant responsive element, in the promoter region of antioxidant genes, including HO-1 and thioredoxin 1.
- ThS exhibits effects on mitochondria function antioxidant stress apoptosis, inflammation angiogenesis, sepsis and shock and blood pressure.
- ThS protects against NO3 , as does glutathione. ThS also significantly reduces the toxic effects of HOC1. ThS enhances the antioxidant effects of N-acetyl-l-cysteine (NAC).
- NAC N-acetyl-l-cysteine
- ThS therapeutic effects have been most studied to date in regard to heart disease. ThS effects on heart disease include macrophages are able to produce ThS endogenously. NaHS (a ThS donor) inhibited pro-atherogenic oxidized low-density lipoproteins induced foam cell formation in macrophages. ThS is able to down regulate ROS at the mitochondria, providing protection through reduced respiration. ThS production (10-100 nM) enhanced mitochondrial electron transport and cellular bioenergetics however at high concentrations ThS is toxic. ThS in the diet decreased adverse left ventricle (LV) remodeling during heart failure. ThS can upregulate endothelial nitric oxide synthase which makes NO and NO can upregulate the ThS synthesis enzyme CSE.
- LV adverse left ventricle
- ThS phosphorylation effecting eNOS suggesting active cross talk between ThS and NO. There also appears to be cross talk between CO and ThS. ThS induces vasodilation, leading to reduced blood pressure. ThS in the form of Na2S (10 minutes prior) prevents reperfusion injury. Exogenous ThS also led to improved renal function.
- ThS under in vivo conditions has an extremely short half-life which is estimated to be between seconds and minutes.
- Plasma concentrations of ThS is in the range of 0.034 to 0.065 mM, in the brain it is three-fold higher than the plasma.
- ThS concentration are inversely related to O2 concentration and ThS decrease cellular O2 consumption.
- ThS concentrations of between 0.030 and 0.300 have also been reported in the blood and plasma.
- H2S donors NaHS and Na?S increase H2S concentration within seconds to minutes.
- H2S The physiological range of H2S is widely variable from 0.005 to 0.300 mM. Endogenous levels of EES in the brains of humans have been detected at from 0.05 to 0.16 mM; in the brains of Alzheimer’s patients, the EES concentration is lower. Diallyl trisulfide (DATS) is a stable EES donor and shows effects 30 minutes after injection and is longer lasting. NaHS can be taken in drinking water. NaHS (H2S donor), in aqueous solution releases 3 ⁇ 4S, in drinking water for 6 weeks. There was an increase in plasma 3 ⁇ 4S concentration with exogenous supplementation. There was no difference in the consumption of water among the groups of mice treated with NaHS and untreated groups.
- DATS Diallyl trisulfide
- 3 ⁇ 4S donors include GYY 4137 (CAS# 106740-09-4) a water soluble 3 ⁇ 4S donor that slowly releases 3 ⁇ 4S over the course of hours and SG 1002 from Sulfagenix, Inc.
- AP97, AP39, AP67, and AP105 are also 3 ⁇ 4S donors with slower release.
- 3 ⁇ 4S can be ingested with foods containing organosulfides, who’s polysulfides can be 3 ⁇ 4S donors.
- 3 ⁇ 4S can be inhaled and inhalation increases blood 3 ⁇ 4S levels (40 ppm for 8 hours for 7 days was used with mice). Inhalation can also be combined with ingestible H2S donors such as Na2S and NaHS. Measurement of H2S in blood and tissue has been done with a sensitive and reliable means.
- H2S can also be stored in cells in the form of sulfane sulfur and transported and released in response to physiological stimulus.
- FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H2S) donor. FW1256 inhibits NF-KB activity and induces cell apoptosis. FW1256 exerts potent anti inflammatory effects and has the potential for cancer and cardiovascular disease treatment.
- H2S hydrogen sulfide
- Nrf2 The transcription factor NF-E2 p45-related factor 2 (Nrf2: gene name NFE212) regulates the expression of networks of genes encoding proteins with diverse cytoprotective activities. Nrf2 itself is controlled primarily at the level of protein stability. Nrf2 is a short lived protein subjected to continuous ubiquitination and protease degradation. There are three known ubiquitin ligase systems that contribute to the degradation of Nrf2 a) Keap-1, a substrate adaptor protein for Cullin-3, b) glycogen synthase kinase, and c) E3 ubiquitin ligase Hrdl. Keap-1 is also a sensor for a wide array of small-molecule activators also called inducers.
- Nrf2 When Nrf2 is not degraded and is translocated to the nucleus it forms a heterodimer with a small Maf protein, binds to antioxidant-response elements which are the upstream regulatory regions of its target genes and initiates transcription.
- Nrf2 is a master regulator of cellular redox homeostasis. Over 50 genes are regulated by Nrf2 in humans. In a direct effect of inflammation genes, without a Redox mechanism, Nrf2 also binds to the upstream region of the IL6 gene and when bound can significantly disrupt the recruitment of RNA polymerase II to regulate the transcription of IL6 in human macrophage cells.
- Nrf2 signaling is regulated by transcriptional, translational, posttranslational, and epigenetic mechanisms as well as by other protein partners including p62, p21 and IQ motif containing GTPase activating protein 1.
- Nuclear factor erythroid 2 (Nrf2) activators include classes of activators with activities that: induce nuclear translocation of Nrf2, increase Nrf2 mRNA transcription, increase protein expression of Nrf2 and increase Nrf2 downstream target genes. There are also Nrf2 inhibitors (Bach 1, caveolae, TGF-beta). The Keapl-Nrf2 pathway acts in concert with autophagy to combat proteotoxicity.
- Keap-1 is a zinc metalloprotein that is localized near the plasma membrane. It has three functional domains, at least 25 reactive thiols most of which are found in the intervening linker region. Keap-1 has an Nrf2 binding site on each dimer subunit forming a “latch and hinge.” Keap-1 is highly sensitive to oxidation and its different thiol groups have different redox potentials. These different cysteine residues create a sensor system.
- Nrf2 is a 605 amino acid transcription factor composed of six domains.
- the N- terminal Neh2 domain is the binding site for the inhibitory protein Keap-1.
- the half-life of Nrf2 when separated from Keap-1 is 20 minutes.
- Keap-1 is exported out of the nucleus in 0.5 hours. Nrf2 activations enhances Sirtl activity in mice fibroblasts cell culture.
- Nrf2 When Nrf2 releases Keap-1 it is available to capture IKKBeta thus inhibiting NF-KB target genes. This interaction correlates the expression of antioxidant enzymes by NrF2 and the turning on and off of the immune system by NF-KB.
- Nrf2 and NF-kB compete for CREB-binding protein (CBP).
- CBP CREB-binding protein
- Phenolics that appear to act most directly on Nrf2 are ortho- or para- dihydroxyphenols which can be oxidized to quinones.
- Quinones are oxidized derivatives of aromatic compounds and are often readily made from reactive aromatic compounds with electron-donating substituents such as phenols and catechols, which increase the nucleophilicity of the ring and contributes to the large redox potential needed to break aromaticity.
- Quinones are conjugated but not aromatic.
- Quinones are electrophilic Michael acceptors stabilized by conjugation. Depending on the quinone and the site of reduction, reduction can either re-aromatize the compound or break the conjugation. Conjugate addition nearly always breaks the conjugation.
- Nrf2 activators listed separately above. Everything mentioned that is aNrf2 activator, is also an antioxidant defense system activator although some things activated by Nrf2 may be seen as additional to antioxidant defense system activation. The activation comes from the multiple ways listed above of keeping the Nrf2 system on.
- One form of regulation of Nrf2 is reversible phosphorylation.
- Sirtl and PARP1 as discussed before can also be reversibly phosphorylated.
- Nrf2 activation and the turning on of the antioxidant defense system needs to be correlated in timing to NAD+ availability and methylation availability and be synced with the biological clock NAD+ peaks of the person.
- the Nrf2 system does need to turn off (example: around 2 pm when NAD+ concentrations normally are at their daily biological clock low) so one’s body can do the things it needs to do under a redox balance when that leans towards oxidation.
- Antioxidant defense activators such as Nuclear factor erythroid 2 (Nrf2) activators (including activities such as: nuclear translocation of Nrf2, increasing Nrf2 mRNA transcription, increasing protein expression of Nrf2 and increasing Nrf2 downstream target genes), zinc, calcium peroxide, N-Acetylcysteine, H2O2, ROS, RNS, RCS, RSOH, O2 1 , O2, EES, O3, HOC1, HOBr, HOI, ROOH, where R is alkyl, cycloalkyl, heteralkyl, heterocycloalkyl, alkenyl, heteroalkenyl, cycloalkenyl, or hetercycloalkenyl, H2O2 generator, such as metformin or acetaminophen, ortho hydroxyphenols which can be oxidized to quinones, para dihydroxyphenols which can be oxidized to quinones, quinones (are oxidized derivatives of aromatic compounds), hydrogen sulfide (H2
- the disclosed compositions can comprise nicotinamide adenine dinucleotide (NAD+), Betaine, and Zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), folate + Vitamin B12, and Zinc (e.g, as zinc sulfate).
- the disclosed compositions e.g, nutritional compositions
- the disclosed composition can comprise nicotinamide riboside (NR), Methionine, and Zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Choline, and Zinc (e.g, as zinc sulfate).
- the disclosed compositions can comprise nicotinamide adenine dinucleotide (NAD+), Betaine, and H2O2.
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), folate + Vitamin B 12, and H2O2.
- the disclosed compositions e.g, nutritional compositions
- the disclosed composition can comprise nicotinamide riboside (NR), Methionine, and H2O2.
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Choline, and H2O2.
- the disclosed compositions can comprise nicotinamide adenine dinucleotide (NAD+), Betaine, and NaHS.
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Folate + Vitamin B 12, and NaHS.
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Methionine, and NaHS.
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Choline, and NaHS.
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Betaine, and Na2S.
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Folate + Vitamin B12, and Na2S.
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Methionine, and Na2S.
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Choline, and Na2S.
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Betaine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3 ,4-dihyfroxyphenyl ethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Folate + Vitamin B12, and any one or more of H?S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4- dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl-l, 2, 4-triazole derivatives, 6-Shogaol, Acetyl
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Methionine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2,3- triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acety
- the disclosed composition can comprise nicotinamide adenine dinucleotide (NAD+), Choline, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1,4- diphenyl-1, 2, 3-triazoles, 15 -deoxy-D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3 -alkyl amino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl- 11
- the disclosed compositions can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine, and zinc (e.g, as zinc sulfate).
- NMN nicotinamide mononucleotide
- Betaine a precursor or prodrug of NMN
- zinc e.g, as zinc sulfate
- the disclosed composition can comprise nicotinamide riboside (NR), Betaine, and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), with Betaine, and zinc ( e.g ., as zinc sulfate).
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine, and zinc (e.g., as zinc sulfate).
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- Betaine Betaine
- zinc e.g., as zinc sulfate
- compositions wherein the first compound comprises NMN.
- compositions wherein the first compound comprises a precursor or prodrug of NMN, e.g, a compound that increases NMN production in the body.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, folate + Vitamin B12, and zinc (e.g, as zinc sulfate).
- NMN nicotinamide mononucleotide
- NR nicotinamide riboside
- folate + Vitamin B12 a precursor or prodrug of NMN
- zinc e.g, as zinc sulfate
- the disclosed composition can comprise nicotinamide riboside (NR), folate + Vitamin B12, and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), folate + Vitamin B12, and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), folate + Vitamin B12, and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine + Vitamin B12, and zinc (e.g, as zinc sulfate).
- NMN nicotinamide mononucleotide
- Betaine + Vitamin B12 a precursor or prodrug of NMN
- zinc e.g, as zinc sulfate
- the disclosed composition can comprise nicotinamide riboside (NR), Betaine + Vitamin B 12, and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine + Vitamin B12, and zinc (e.g, as zinc sulfate).
- NaMN nicotinic acid adenine mononucleotide
- NaAD nicotinic acid adenine dinucleotide
- NAR nicotinic acid riboside
- Betaine + Vitamin B12 e.g, as zinc sulfate
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine + Vitamin B12, and zinc (e.g, as zinc sulfate).
- MNM 1-methylnicotinamide
- cAMP cyclic adeno
- the disclosed compositions can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Methionine, and zinc (e.g, as zinc sulfate).
- NMN nicotinamide mononucleotide
- NR nicotinamide riboside
- Methionine nicotinamide riboside
- zinc e.g, as zinc sulfate
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), with Methionine, and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Methionine, and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Choline, and zinc (e.g., as zinc sulfate).
- the disclosed composition can comprise nicotinamide riboside (NR), Choline, and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Choline, and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Choline, and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, S-Adenosyl-methionine (SAM), and zinc (e.g, as zinc sulfate).
- NMN nicotinamide mononucleotide
- SAM S-Adenosyl-methionine
- zinc e.g, as zinc sulfate
- the disclosed composition can comprise nicotinamide riboside (NR), S-Adenosyl-methionine (SAM), and zinc (e.g, as zinc sulfate).
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), S-Adenosyl-methionine (SAM), and zinc (e.g, as zinc sulfate).
- NaMN nicotinic acid adenine mononucleotide
- NaAD nicotinic acid adenine dinucleotide
- NAR nicotinic acid riboside
- SAM S-Adenosyl-methionine
- zinc e.g, as zinc sulfate
- the disclosed composition can comprise 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), S-Adenosyl- methionine (SAM), and zinc (e.
- the disclosed compositions can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine, and H2O2.
- the disclosed composition can comprise nicotinamide riboside (NR), Betaine, and H2O2.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), with Betaine, and H2O2.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine, and H2O2.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- Betaine Betaine
- H2O2O2 H2O2
- compositions wherein the first compound comprises NMN Also disclosed are compositions wherein the first compound comprises a precursor or prodrug of NMN, e.g, a compound that increases NMN production in the body.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, folate + Vitamin B12, and H2O2.
- the disclosed composition can comprise nicotinamide riboside (NR), folate + Vitamin B12, and H2O2.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), folate + Vitamin B12, and H 2 O 2.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), folate + Vitamin B 12, and H 2 O 2.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine + Vitamin B12, and H 2 O 2.
- the disclosed composition can comprise nicotinamide riboside (NR), Betaine + Vitamin B12, and H 2 O 2.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine + Vitamin B12, and H 2 O 2.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine + Vitamin B12, and H2O2.
- the disclosed compositions can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Methionine, and H 2 O 2.
- the disclosed composition can comprise nicotinamide riboside (NR), Methionine, and H 2 O 2.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), with Methionine, and H 2 O 2.
- the disclosed composition can comprise 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Methionine, and H2O2.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Choline, and H 2 O 2.
- the disclosed composition can comprise nicotinamide riboside (NR), Choline, and H 2 O 2.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Choline, and H 2 O 2.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Choline, and H 2 O 2.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, S-Adenosyl-methionine (SAM), and H 2 O 2.
- the disclosed composition can comprise nicotinamide riboside (NR), S-Adenosyl-methionine (SAM), and H 2 O 2.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), S- Adenosyl-methionine (SAM), and H2O2.
- NaMN nicotinic acid adenine mononucleotide
- NaAD nicotinic acid adenine dinucleotide
- NAR nicotinic acid riboside
- SAM S- Adenosyl-methionine
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- SAM S-Adenosyl-methionine
- H2O2 can be replaced with calcium peroxide or N-Acetylcysteine.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine, and NaHS.
- the disclosed composition can comprise nicotinamide riboside (NR), Betaine, and NaHS.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine, and NaHS.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine, and NaHS.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Folate + Vitamin B12, and NaHS.
- the disclosed composition can comprise nicotinamide riboside (NR), Folate + Vitamin B12, and NaHS.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Folate + Vitamin B12, and NaHS.
- the disclosed composition can comprise 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Folate + Vitamin B 12, and NaHS.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine + Vitamin B12, and NaHS.
- the disclosed composition can comprise nicotinamide riboside (NR), Betaine + Vitamin B 12, and NaHS.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine + Vitamin B12, and NaHS.
- the disclosed composition can comprise 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine + Vitamin B 12, and NaHS.
- MNM 1- methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Methionine, and NaHS.
- the disclosed composition can comprise nicotinamide riboside (NR), Methionine, and NaHS.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Methionine, and NaHS.
- NaMN nicotinic acid adenine mononucleotide
- NaAD nicotinic acid adenine dinucleotide
- NAR nicotinic acid riboside
- Methionine Methionine
- NaHS NaHS
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Methionine, and NaHS.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Choline, and NaHS.
- the disclosed composition can comprise nicotinamide riboside (NR), Choline, and NaHS.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Choline, and NaHS.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Choline, and NaHS.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, S-Adenosyl-methionine (SAM), and NaHS.
- the disclosed composition can comprise nicotinamide riboside (NR), S-Adenosyl-methionine (SAM), and NaHS.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), S-Adenosyl-methionine (SAM), and NaHS.
- NaMN nicotinic acid adenine mononucleotide
- NaAD nicotinic acid adenine dinucleotide
- NAR nicotinic acid riboside
- SAM S-Adenosyl-methionine
- NaHS NaHS
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), S-Adenosyl-methionine (SAM), and NaHS.
- MNM 1-methylnicotinamide
- cAMP cyclic aden
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine, and Na?S.
- the disclosed composition can comprise nicotinamide riboside (NR), Betaine, and Na2S.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine, and Na?S.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine, and Na?S.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Folate + Vitamin B12, and Na2S.
- the disclosed composition can comprise nicotinamide riboside (NR), Folate + Vitamin B12, and Na2S.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Folate + Vitamin B12, and Na2S.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Folate + Vitamin B12, and Na2S.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine + Vitamin B12, and Na2S.
- the disclosed composition can comprise nicotinamide riboside (NR), Betaine + Vitamin B12, and Na2S.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine + Vitamin B12, and Na2S.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine + Vitamin B12, and Na 2 S.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Methionine, and Na2S.
- the disclosed composition can comprise nicotinamide riboside (NR), Methionine, and Na2S.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Methionine, and Na2S.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Methionine, and Na2S.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Choline, and Na2S.
- the disclosed composition can comprise nicotinamide riboside (NR), Choline, and Na2S.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Choline, and Na2S.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Choline, and Na2S.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, S-Adenosyl-methionine (SAM), and Na2S.
- the disclosed composition can comprise nicotinamide riboside (NR), S-Adenosyl-methionine (SAM), and Na?S.
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), S- Adenosyl-methionine (SAM), and Na?S.
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), S-Adenosyl-methionine (SAM), and Na?S.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine, and any one or more of IBS, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1,4- diphenyl-1, 2, 3-triazoles, 15 -deoxy-D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol
- the disclosed composition can comprise nicotinamide riboside (NR), Betaine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1,4- diphenyl-1, 2, 3-triazoles, 15 -deoxy-D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl- 11 -keto ⁇ -bos
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-al
- the disclosed composition can comprise 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shoga
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Folate + Vitamin B12, and any one or more of H?S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4- dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl-l, 2, 4-triazole derivatives, 6-S
- the disclosed composition can comprise nicotinamide riboside (NR), Folate + Vitamin B12, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2,3- triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl- 1 l-
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Folate + Vitamin B12, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxypheny
- the disclosed composition can comprise 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Folate + Vitamin B12, and any one or more of FhS, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl- 1,2, 4-triazole derivatives,
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine + Vitamin B12, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-
- the disclosed composition can comprise nicotinamide riboside (NR), Betaine + Vitamin B12, and any one or more of FhS, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2,3- triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl- 1 l-
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine + Vitamin B12, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxypheny
- the disclosed composition can comprise 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine + Vitamin B12, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl- 1,2, 4-triazole derivatives, 6-
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Methionine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4- dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl-l, 2, 4-triazole derivatives, 6-Shoga
- the disclosed composition can comprise nicotinamide riboside (NR), Methionine, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl-1 l-keto ⁇ -bo
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Methionine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4- dihyfroxyphenylethanol, 3-
- the disclosed composition can comprise 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Methionine, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shog
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Choline, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1,4- diphenyl-1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3 -alkyl amino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shog
- the disclosed composition can comprise nicotinamide riboside (NR), Choline, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1,4- diphenyl-1, 2, 3-triazoles, 15 -deoxy-D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3 -alkyl amino- IH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl- 11 -keto ⁇ -bos
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Choline, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-
- the disclosed composition can comprise 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Choline, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogao
- the disclosed composition can comprise nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, S-Adenosyl-methionine (SAM), and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl-
- the disclosed composition can comprise nicotinamide riboside (NR), S-Adenosyl-methionine (SAM), and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1,4- diphenyl-1, 2, 3-triazoles, 15 -deoxy-D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3 -alkyl amino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogao
- the disclosed composition can comprise one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), S- Adenosyl-methionine (SAM), and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-
- the disclosed composition can comprise 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), S-Adenosyl-methionine (SAM), and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2,3- triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino- lH-indole acrylates, 4-phenyl- 1,
- the combined amounts of compounds of category 1, 2, and 3 in the composition can be at least 5 wt.% of the composition.
- the repair system activator, the methyl donor, and the antioxidant defense activator can be at least 5 wt.% of the composition.
- the combined amount of compounds of category 1, 2, and 3 in the composition can be at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 70, at least 75, at least 80, at least 85, at least 90, at least 95, or 100 wt.% of the composition, where any of the stated values can form an upper or lower endpoint of a range.
- NNN Cocktail The herein described “unit dose”, “formulation”, and/or “composition” may be referred to as an “NMN Cocktail”.
- Formulations which can be packaged in a powder or lyophilized form, which can then have either hot or cold liquid added to them for reconstituting into a solution are disclosed.
- the disclosed compositions could be mixed with compositions, such as is done in personal beverage systems, which make hot or cold coffee or tea or hot chocolate from individually packaged components and the addition of water.
- the disclosed compositions can be administered in vivo either alone or in a pharmaceutically acceptable carrier.
- pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material can be administered to a subject, along with the composition disclosed herein, without causing any undesirable biological effects.
- the carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.
- the materials can be in solution, suspension (for example, incorporated into microparticles, liposomes, or cells).
- the mammalian intestinal microbiota is composed of up to 100 trillion microbes from over 500 genera of bacteria from two main phyla, namely Bacteroidetes and Firmicutes.
- a well-studied mammalian probiotic Lactobacillus rhamnosus GG is a potent inducer of ROS.
- Redox signaling mediates symbiosis between the gut microbiota and the intestine. In flies, increase in life span is correlated to increase formation of the oxidant H2O2 in the gut.
- FhS protects the mucosal lining of the gastrointestinal tract against oxidative stress as well as regulates various functions including fluid transport, inflammation, acid induced HCO3 secretion.
- Gut microbiota composition in the elderly has been correlated to plasma 11-6 levels.
- Crtc A fasting molecule Crtc enhances immunity by making the gut barrier less permeable to bacteria. Gut bacteria that get across the gut barrier cause inflammation. This Crtc is a genetic switch in the brain that controls energy balance. This constant communication between the brain and the GI tract allows the body to keep tract of energy expenditures and stores. Crtc interacts with CREB (cAMP response element-binding protein). A partner of Crtc in the human brain is neuropeptide Y, which causes mammals to search for food. CREB activity is regulated by energy sensing Sirtl and its ability to deacetylate CREB. This links the level of NAD+ and the feeling of hunger.
- CREB cAMP response element-binding protein
- the glucose- regulated antagonism between (yet coordinated with) CREB and Sirtl for Hes-1 transcription participates in the metabolic regulation of neurogenesis, this is important since a decline in neurogenesis accompanies brain aging and CREB transcription factor is activated by nutrient deprivation which is correlated to Sirtuin enzyme activity.
- TNF in the circulation of humans that occurs as part of the aging process impairs inflammatory monocyte development function and is detrimental to anti -pneumococcal immunity. This is reversed with pharmacological reduction of TNF.
- the formulation could have organisms such as bacteria in the microbiome extrude any or all of these three categories of compounds that are desired and add them directly into the gut. These organisms could extrude the desired compounds in the quantity and with the timing desired. These organisms could be introduced to the microbiome either from a selection of organisms that naturally occur in the microbiome or by the engineering of organisms that naturally occurs in the microbiome. The engineered organisms could be engineered to extrude these compounds in accordance to the introduced organism’s and or the host’s biological clock. The introduced organism could be engineered to extrude the desired amount of compound or compounds. Gene-drive could be used to switch all of the species in the gut of this type used to the introduced organism’s gene type desired. A kill switch could be engineered into this introduced species as well to allow an elimination of these engineered species if they were not desired later.
- compositions disclosed herein can be used therapeutically in combination with a pharmaceutically acceptable carrier.
- Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (22nd ed.) ed. L.V. Loyd Jr., CBS Publishers & Distributors Grandville MI USA 2012.
- an appropriate amount of a pharmaceutically acceptable salt is used in the formulation to render the formulation isotonic.
- the pharmaceutically acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution.
- the pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5.
- Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers can be more preferable depending upon, for instance, the route of administration and concentration of composition being administered.
- compositions can be administered intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.
- compositions can include carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice.
- Pharmaceutical compositions can also include one or more active ingredients such as antimicrobial agents, anti-inflammatory agents, anesthetics, and the like.
- the pharmaceutical composition can be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration can be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, intraperitoneal or intramuscular injection.
- the disclosed compounds can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.
- Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles include sodium chloride solution, Ringer’s dextrose, dextrose and sodium chloride, lactated Ringer’s, or fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer’s dextrose), and the like. Preservatives and other additives can also be present such as, for example, antimicrobials, chelating agents, and inert gases and the like.
- Formulations for topical administration can include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
- Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
- compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders may be desirable.
- compositions can be administered as a pharmaceutically acceptable acid- or base- addition salt, formed by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.
- inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid
- organic acids such as formic acid, acetic acid, propionic acid, glycolic
- the various compounds and compositions of categories 1, 2, and 3, can be taken at the same time or in proximity, such as within 1, 5, 10, 30, 60, 90, or 120 minutes.
- the disclosed composition can comprise nicotinamide mononucleotide (NMN), Betaine, and Zinc Sulfate in a ratio of from about 7 and 20: to from about 4 and 10; to about 1.
- the composition further comprises about a ratio of NaCl (to the other components) of from about 0.25 and about 1.25.
- a unit dose of the composition comprises from about 0.8 grams and about 2.0 grams of NMN, from about 0.4 grams and 0.8 grams of Betaine, and from about 0.09 and 0.25 grams of Zinc Sulfate. In embodiments, the unit dose of the composition comprises from about 0.9 grams and about 1.1 grams of NMN, from about 0.45 grams and 0.55 grams of Betaine, and from about 0.1 and 0.12 grams of Zinc Sulfate. In embodiments, the unit dose of the composition comprises about 1 gram of NMN, 0.5 grams of Betaine, and about 0.11 grams of Zinc Sulfate. In embodiments, the unit dose further comprises from about 25 mg to about 100 mg of NaCl. In embodiments, the unit dose further comprises about 50 mg of NaCl.
- NNN Cocktail The herein described “unit dose”, “formulation”, and/or “composition” may be referred to as an “NMN Cocktail”.
- At least one unit of a composition is administered to the subject at each dosing.
- at least two units of the composition, at least three units of the composition, at least four units of the composition, or at least five units of the composition is administered to the subject at each dosing.
- the number of units of the composition per dosing relates in part to the weight of the subject.
- the subject when a subject weighs 100 lbs or less, the subject is administered at least one unit of the composition per dosing and/or when a subject weighs over 100 lbs, the subject is administered at least one unit, at least two units, at least three units, or at least four units or at least five units of the composition per dosing.
- the subject receives at least one dosing per day, at least two dosings per day, at least three dosings per day, or at least four dosings per day.
- a delivery system in water is preferable if the preferred ingredient of category 1, 2 and 3 are used. This will help elicit the correct timing (all 3 preferred ingredients are easily absorbed and soluble in water). For some other less preferred ingredients, which are not as water soluble or are not as easily absorbed their delivery would result in a reduced benefit with respect to the pulse timing of these three categories of ingredients.
- a viral infection e.g caused by SARS-CoV-2
- Illustrative viral infections may be caused by one or more of enteroviruses A-J; rhinoviruses A-C; rotaviruses A-C; norovirus; influenza virus A-C and their several types like H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, H7N9, and their other relatives; human papillomaviruses (HPV); polyomaviruses like John Cunningham virus (JCV) and Merkel cell virus (MCV); poxviruses; herpesviruses such as human simplex virus 1 (HSV- 1), human simplex virus 2 (HSV-2), varicella zoster virus, Epstein-Barr virus (human herpesvirus 4; EBV/HHV-4), human cytomegalovirus (HHV-5), Herpesvirus 6 (A&B), herpesvirus 7, and Kaposi's sarcoma-associated herpesvirus
- composition in accordance with the subject is administered the composition in accordance with the subject’s circadian rhythm.
- compositions are administered to a subject a dosage of at least 1 x 10 8 moles of the first compound to the subject, 1 x 10 8 moles of the second compound to the subject, and 1 x 10 9 moles of the third compound to the subject.
- composition is injected over 8-12 days.
- composition is an aerosol, lyophilization, powder, or emulsion.
- composition is a tablet that is administered orally at least once daily.
- composition is administered once daily.
- compositions can be administered at a variety of dosages.
- category 1 compounds like Nicotinamide Mononucleotide (NMN), can be at dosages per day of 1 x 10 6 moles/kg to 1 x 10 2 moles/kg or 1 x 10 5 moles/kg to 1 x 10 3 moles/kg or 1 x 10 4 moles/kg to 1 x 10 3 moles/kg or 2 x 10 4 moles/kg to 7 x 10 4 moles/kg.
- NPN Nicotinamide Mononucleotide
- the dosages per day of the category 1 molecule can be at least 1 x 10 6 moles/kg, 1 x 10 5 moles/kg, 1 x 10 4 moles/kg, 1 x 10 3 moles/kg or 1 x 10 2 moles/kg.
- the dosages can also be at least 2.38 moles/kg per day.
- the same dosages are contemplated herein for other category 1 compounds NAD+, NR, NaMN, NaAD, NAR, MNM, and cAMP.
- the dosage of category 2 compounds can be at dosages per day of 1 x 10 6 moles/kg to 1 x 10 2 moles/kg or 1 x 10 5 moles/kg to 1 x 10 3 moles/kg or 1 x 10 4 moles/kg to 1 x 10 3 moles/kg or 2 x 10 4 moles/kg to 7 x 10 4 moles/kg.
- the dosages per day of the category 2 compound can be at least 1 x 10 6 moles/kg, 1 x 10 5 moles/kg, 1 x 10 4 moles/kg, 1 x 10 3 moles/kg or 1 x 10 2 moles/kg.
- the dosages can also be at least 5.82 x 10 4 moles / kg body weight / day.
- the dosages of category 3 compounds can be at dosages per day of 1 x 10 7 moles/kg to 1 x 10 2 moles/kg or 1 x 10 6 moles/kg to 1 x 10 3 moles/kg or 1 x 10 5 moles/kg to 1 x 10 4 moles/kg or 1 x 10 5 moles/kg to 7 x 10 5 moles/kg.
- the dosages per day of the category 3 compound can be at least 1 x 10 7 moles/kg, 1 x 10 6 moles/kg, 1 x 10 5 moles/kg, 1 x 10 4 moles/kg or 1 x 10 3 moles/kg.
- the dosages can also be at least dosage 2.34 x 10 5 moles / kg body weight / day.
- the dosages of category 3 compounds can be at dosages per day of 1 x 10 7 moles/kg to 1 x 10 2 moles/kg or 1 x 10 6 moles/kg to 1 x 10 3 moles/kg or 1 x 10 5 moles/kg to 1 x 10 4 moles/kg or 1 x 10 5 moles/kg to 7 x 10 5 moles/kg.
- the dosages per day of the category 3 compound can be at least 1 x 10 7 moles/kg, 1 x 10 6 moles/kg, 1 x 10 5 moles/kg, 1 x 10 4 moles/kg or 1 x 10 3 moles/kg.
- the dosages can also be at least dosage 2.34 x 10 5 moles / kg body weight / day.
- the dosages of category 3 compounds can be at dosages per day of 1 x 10 7 moles/kg to 1 x 10 2 moles/kg or 1 x 10 6 moles/kg to 1 x 10 3 moles/kg or 1 x 10 5 moles/kg to 1 x 10 4 moles/kg or 1 x 10 5 moles/kg to 7 x 10 5 moles/kg.
- the dosages per day of the category 3 compound can be at least 1 x 10 7 moles/kg, 1 x 10 6 moles/kg, 1 x 10 5 moles/kg, 1 x 10 4 moles/kg or 1 x 10 3 moles/kg.
- the dosages can also be at least dosage 2.34 x 10 5 moles / kg body weight / day.
- the dosages of category 3 compounds, such as H2O2 can be at dosages per day of 1 x 10 7 moles/kg to 1 x 10 2 moles/kg or 1 x 10 6 moles/kg to 1 x 10 3 moles/kg or 1 x 10 5 moles/kg to 1 x 10 4 moles/kg or 1 x 10 5 moles/kg to 7 x 10 5 moles/kg.
- the dosages per day of the category 3 compound can be at least 1 x 10 7 moles/kg, 1 x 10 6 moles/kg, 1 x 10 5 moles/kg, 1 x 10 4 moles/kg or 1 x 10 3 moles/kg.
- the dosages can also be at least dosage 2.34 x 10 5 moles / kg body weight / day.
- the dosages of category 3 compounds can be at dosages per day of 1 x 10 8 moles/kg to 1 x 10 3 moles/kg or 1 x 10 7 moles/kg to 1 x 10 4 moles/kg or 1 x 10 6 moles/kg to 1 x 10 5 moles/kg or 1 x 10 6 moles/kg to 7 x 10 6 moles/kg.
- the dosages per day of the category 3 compound can be at least 1 x 10 8 moles/kg, 1 x 10 7 moles/kg, 1 x 10 6 moles/kg, 1 x 10 4 moles/kg or 1 x 10 3 moles/kg.
- the dosages can also be at least 3.02 x 10 6 moles / Kg body weight / day.
- a viral infection e.g caused by SARS-CoV-2
- Illustrative viral infections may be caused by one or more of enteroviruses A-J; rhinoviruses A-C; rotaviruses A-C; norovirus; influenza virus A-C and their several types like H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, H7N9, and their other relatives; human papillomaviruses (HPV); polyomaviruses like John Cunningham virus (JCV) and Merkel cell virus (MCV); poxviruses; herpesviruses such as human simplex virus 1 (HSV- 1), human simplex virus 2 (HSV-2), varicella zoster virus, Epstein-Barr virus (human herpesvirus 4; EBV/HHV-4), human cytomegalovirus (HHV-5), and Herpesvirus 6 (A&B), herpesvirus 7, Kaposi's sarcoma-associated herpesvirus
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), S-Adenosyl-methionine (SAM), and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), S-Adenosyl-methionine (SAM), and H2O2.
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), S-Adenosyl-methionine (SAM), and NaSH.
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), S-Adenosyl-methionine (SAM), and Na2S.
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), S-Adenosyl-methionine (SAM), and any one or more of 3 ⁇ 4S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles,
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Betaine, and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), folate + Vitamin B12, and zinc (e.g., as zinc sulfate).
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Methionine, and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Methionine, and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Choline, and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Betaine, and H 2 O 2.
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), folate + Vitamin B12, and H 2 O 2.
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Methionine, and H 2 O 2.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Methionine, and H 2 O 2.
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Choline, and H 2 O 2.
- H 2 O 2 can be replaced with calcium peroxide or N-Acetylcysteine.
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Betaine, and NaHS. In specific examples, the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Folate + Vitamin B 12, and NaHS. In specific examples, the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Methionine, and NaHS. In specific examples, the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Choline, and NaHS.
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Betaine, and Na 2 S. In specific examples, the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Folate + Vitamin B12, and Na 2 S. In specific examples, the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Methionine, and Na 2 S. In specific examples, the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Choline, and Na 2 S.
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Betaine, and any one or more of IBS, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1,4- diphenyl-1, 2, 3-triazoles, 15 -deoxy-D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3 -alkyl amino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Folate + Vitamin B12, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2,3- triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-S, nic
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Methionine, and any one or more of FhS, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl- 1,2, 4-triazole derivatives, 6-Shogaol
- the disclosed methods can comprise administering to a subject nicotinamide adenine dinucleotide (NAD+), Choline, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Ace
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine, and zinc (e.g, as zinc sulfate).
- NMN nicotinamide mononucleotide
- Betaine a precursor or prodrug of NMN
- zinc e.g, as zinc sulfate
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Betaine, and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), with Betaine, and zinc (e.g, as zinc sulfate).
- NaMN nicotinic acid adenine mononucleotide
- NaAD nicotinic acid adenine dinucleotide
- NAR nicotinic acid riboside
- the disclosed methods can comprise administering to a subject 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine, and zinc (e.g, as zinc sulfate).
- MNM methylnicotinamide
- cAMP cyclic adenosine monophosphate
- Betaine cyclic a
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, folate + Vitamin B12, and zinc (e.g, as zinc sulfate).
- NMN nicotinamide mononucleotide
- NR nicotinamide riboside
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), folate + Vitamin B12, and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), folate + Vitamin B 12, and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), folate + Vitamin B12, and zinc (e.g, as zinc sulfate).
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine + Vitamin B12, and zinc (e.g, as zinc sulfate).
- NMN nicotinamide mononucleotide
- NR nicotinamide riboside
- Betaine + Vitamin B12 e.g., as zinc sulfate
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine + Vitamin B12, and zinc (e.g, as zinc sulfate).
- NaMN nicotinic acid adenine mononucleotide
- NaAD nicotinic acid adenine dinucleotide
- NAR nicotinic acid riboside
- Betaine + Vitamin B12 e.g, as zinc sulfate
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine + Vitamin B12, and zinc (e.g, as zinc sulfate).
- MNM 1-methylnicotinamide
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Methionine, and zinc ( e.g ., as zinc sulfate).
- NMN nicotinamide mononucleotide
- NR nicotinamide riboside
- Methionine e.g., as zinc sulfate
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), with Methionine, and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Methionine, and zinc (e.g, as zinc sulfate).
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- Methionine Methionine
- zinc e.g, as zinc sulfate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Choline, and zinc (e.g, as zinc sulfate).
- NMN nicotinamide mononucleotide
- NR nicotinamide riboside
- zinc e.g, as zinc sulfate
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Choline, and zinc (e.g, as zinc sulfate).
- NaMN nicotinic acid adenine mononucleotide
- NaAD nicotinic acid adenine dinucleotide
- NAR nicotinic acid riboside
- Choline e.g, as zinc sulfate
- the disclosed methods can comprise administering to a subject 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Choline, and zinc (e.g, as zinc sulfate).
- MNM methylnicotinamide
- cAMP cyclic aden
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, S-Adenosyl- methionine (SAM), and zinc (e.g, as zinc sulfate).
- NMN nicotinamide mononucleotide
- SAM S-Adenosyl- methionine
- zinc e.g, as zinc sulfate
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), S-Adenosyl- methionine (SAM), and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), S-Adenosyl-methionine (SAM), and zinc (e.g, as zinc sulfate).
- the disclosed methods can comprise administering to a subject 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), S-Adenosyl- methionine (SAM), and zinc (e.g, as zinc sulfate).
- MNM methylnicotinamide
- cAMP cyclic adenosine monophosphate
- SAM S-Adenosyl- methionine
- zinc e.g, as zinc sulfate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine, and H2O2.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Betaine, and H 2 O 2.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), with Betaine, and H 2 O 2.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine, and H 2 O 2.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, folate + Vitamin B12, and H 2 O 2.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), folate + Vitamin B 12, and H 2 O 2.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), folate + Vitamin B12, and H 2 O 2.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), folate + Vitamin B 12, and H 2 O 2.
- MNM 1-methylnicotinamide
- cAMP cyclic
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine + Vitamin B12, and H 2 O 2.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Betaine + Vitamin B 12, and H 2 O 2.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine + Vitamin B12, and H 2 O 2.
- the disclosed methods can comprise administering to a subject 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine + Vitamin B 12, and H 2 O 2.
- MNM methylnicotinamide
- cAMP cycl
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Methionine, and H 2 O 2.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Methionine, and H 2 O 2.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), with Methionine, and H 2 O 2.
- NaMN nicotinic acid adenine mononucleotide
- NaAD nicotinic acid adenine dinucleotide
- NAR nicotinic acid riboside
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Methionine, and H 2 O 2.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Choline, and H 2 O 2 .
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Choline, and H 2 O 2 .
- NR nicotinamide riboside
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Choline, and H 2 O 2 .
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Choline, and H 2 O 2 .
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, S-Adenosyl- methionine (SAM), and H 2 O 2 .
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), S-Adenosyl-methionine (SAM), and H 2 O 2 .
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), S-Adenosyl-methionine (SAM), and H 2 O 2 .
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), S- Adenosyl-methionine (SAM), and H 2 O 2 .
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- SAM S- Adenosyl-methionine
- H 2 O 2 can be replaced with calcium peroxide or N-Acetylcysteine.
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine, and NaHS.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Betaine, and NaHS.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine, and NaHS.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine, and NaHS.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Folate + Vitamin B12, and NaHS.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Folate + Vitamin B12, and NaHS.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Folate + Vitamin B12, and NaHS.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Folate + Vitamin B12, and NaHS.
- MNM 1-methylnicotinamide
- cAMP cyclic a
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine + Vitamin B12, and NaHS.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Betaine + Vitamin B12, and NaHS.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine + Vitamin B12, and NaHS.
- the disclosed methods can comprise administering to a subject 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine + Vitamin B 12, and NaHS.
- MNM methylnicotinamide
- cAMP cyclic a
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Methionine, and NaHS.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Methionine, and NaHS.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Methionine, and NaHS.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Methionine, and NaHS.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Choline, and NaHS.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Choline, and NaHS.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Choline, and NaHS.
- NaMN nicotinic acid adenine mononucleotide
- NaAD nicotinic acid adenine dinucleotide
- NAR nicotinic acid riboside
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Choline, and NaHS.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, S-Adenosyl- methionine (SAM), and NaHS.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), S-Adenosyl-methionine (SAM), and NaHS.
- NR nicotinamide riboside
- SAM S-Adenosyl-methionine
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), S-Adenosyl-methionine (SAM), and NaHS.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), S- Adenosyl-methionine (SAM), and NaHS.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- SAM S- Adenosyl-methionine
- NaHS NaHS
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine, and Na2S.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Betaine, and Na2S.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine, and Na?S.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine, and Na?S.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Folate + Vitamin B12, and Na?S.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Folate + Vitamin B 12, and Na?S.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Folate + Vitamin B12, and Na?S.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Folate + Vitamin B12, and Na?S.
- MNM 1-methylnicotinamide
- cAMP cycl
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine + Vitamin B12, and Na2S.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Betaine + Vitamin B 12, and Na?S.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine + Vitamin B12, and Na?S.
- the disclosed methods can comprise administering to a subject 1- methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine + Vitamin B 12, and Na?S.
- MNM methylnicotinamide
- cAMP cycl
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Methionine, and Na2S.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Methionine, and Na?S.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Methionine, and Na?S.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Methionine, and Na?S.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Choline, and Na2S.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Choline, and Na2S.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Choline, and Na2S.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Choline, and Na2S.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, S-Adenosyl- methionine (SAM), and Na2S.
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), S-Adenosyl-methionine (SAM), and Na2S.
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), S-Adenosyl-methionine (SAM), and Na2S.
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), S- Adenosyl-methionine (SAM), and Na2S.
- MNM 1-methylnicotinamide
- cAMP cyclic adenosine monophosphate
- SAM S- Adenosyl-methionine
- Na2S Na2S.
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine, and any one or more of H?S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4- dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl-l, 2, 4-triazole derivatives
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Betaine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2,3- triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl- 1
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphen
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2,3- triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Folate + Vitamin B12, and any one or more of FhS, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl- 1,2, 4-tri
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Folate + Vitamin B12, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl-
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Folate + Vitamin B12, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihy
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Folate + Vitamin B12, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl- 1,2, 4-tri
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Betaine + Vitamin B12, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl- 1,2, 4-triazo
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Betaine + Vitamin B12, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl-
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Betaine + Vitamin B12, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihy
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Betaine + Vitamin B12, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl- 1,2, 4-tri
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Methionine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl- 1,2, 4-triazole
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Methionine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1,4- diphenyl-1, 2, 3-triazoles, 15 -deoxy-D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3 -alkyl amino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Methionine, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfr
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Methionine, and any one or more of FhS, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2,3- triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino- lH-indole acrylates, 4-phenyl- 1,2, 4-triadi
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, Choline, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetyl cysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4- dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4-phenyl-l, 2, 4-triazole derivatives,
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), Choline, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2,3- triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivatives, 6-Shogaol, Acetyl- 1 l
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), Choline, and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphen
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), Choline, and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2,3- triazoles, 15-deoxy-D12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino- lH-indole acrylates, 4-phenyl- 1,2, 4-triazole derivative
- the disclosed methods can comprise administering to a subject nicotinamide mononucleotide (NMN) or a precursor or prodrug of NMN, S-Adenosyl- methionine (SAM), and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates,
- the disclosed methods can comprise administering to a subject nicotinamide riboside (NR), S-Adenosyl-methionine (SAM), and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3-alkylamino-lH-indole acrylates, 4- phenyl- 1,2, 4-triazole derivatives, 6-Shog
- the disclosed methods can comprise administering to a subject one or more of nicotinic acid adenine mononucleotide (NaMN), nicotinic acid adenine dinucleotide (NaAD), and nicotinic acid riboside (NAR), S- Adenosyl-methionine (SAM), and any one or more of H2S, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N-Acetylcysteine, DHEA, garlic, b- lapachone, pterostilbene, resveratrol, apigenin, zinc, 1, 4-diphenyl- 1, 2, 3-triazoles, 15-deoxy- D 12, 14-prostaglan
- the disclosed methods can comprise administering to a subject 1-methylnicotinamide (MNM) and/or cyclic adenosine monophosphate (cAMP), S-Adenosyl-methionine (SAM), and any one or more of FES, O3, metformin, acetaminophen, sulforaphane, glucoraphanin, curcumin, quercetin, isoquercetin, ginseng, (R)-alpha-lipoic acid, Hydrophilic oxidized derivatives of Lycopene, N- Acetylcysteine, DHEA, garlic, b-lapachone, pterostilbene, resveratrol, apigenin, zinc, 1,4- diphenyl-1, 2, 3-triazoles, 15 -deoxy-D 12, 14-prostaglandin J2, 3,4-dihyfroxyphenylethanol, 3 -alkyl amino- lH-indole
- MNM
- compositions comprising “a” compound of category 3, as an example, can include more than one compound of category 3.
- preventing is meant, at least, avoiding the occurrence of a disease and/or reducing the likelihood of acquiring the disease.
- treating is meant, at least, ameliorating or avoiding the effects of a disease, including reducing a sign or symptom of the disease.
- a “subject” is meant an individual.
- the “subject” can include domesticated animals (e.g, cats, dogs, etc.), livestock (e.g, cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g, mouse, rabbit, rat, guinea pig, etc.), and birds.
- “Subject” can also include a mammal, such as a primate or a human.
- NMN cocktail comprises any NMN containing unit dose, composition, or formulation as disclosed herein.
- Illustrative NMN cocktails include at least one compound from category 1, at least one compound from category 2, and at least one compound from category 3. Any aspect or embodiment described herein can be combined with any other aspect or embodiment as disclosed herein.
- Example 1 Dramatic clinical improvement in ten consecutive acutely ill elderly patients with presumed COVID-19 treated with a cocktail of nicotinamide mononucleotide (NMN), betaine, sodium chloride and zinc sulfate:
- NAD+ is a critical cellular “currency”, facilitating metabolism, oxidation reduction, circadian rhythm, DNA repair, control of aging and the immune system.
- intra-cellular NAD+ drops, with 50-year-old individuals having only half the quantity of NAD+ compared to healthy young individuals. This age associated NAD+ depletion appears to be exacerbated during COVID-19 infections, especially when complicated by cytokine storm.
- Results Patients 1, 4, 7, and 10 were critically ill with documented worsening oxygenation, increasing levels of inflammation biomarkers, and worsening chest x-ray appearance immediately prior to administration of the NMN cocktail. These patients exhibited prompt post treatment clinical improvement, namely 2-3 days till temperature resolution (4 out of 4 patients), ⁇ 5 days until discharge (3 out of 3 patients), prompt chest x-ray improvement (4 out of 4 patients) and dramatic drops in cytokine levels (3 out of 4 patients) within 3 days. Patients 5 and 8 had double pneumonia but no prior films or inflammation tests. Patients 2 and 3 were severely symptomatic outpatient status post failed hydroxychloroquine (HC), Zithromax (Z) and Zinc (Zc) with no chest x-rays performed.
- HC hydroxychloroquine
- Z Zithromax
- Zinc Zinc
- NAD+ the cell’s hydrogen carrier
- redox oxidation -reduction
- Patient 1 was a rapidly deteriorating SARS-CoV-2 positive woman who needed hospitalization. Her room air (RA) O2 saturation suddenly dropped, her pulmonary infiltrates increased and cytokine levels spiked. The experimental remdesivir or any experimental anti-IL6 drug was unavailable for what appeared to be an obvious cytokine storm. With no other treatment available, after signed informed consent from the patient and family, oral NMN was administered with three additional OTC food supplement boosters (the NMN cocktail). Patient 1 dramatically improved within 48 hours. Based on this surprisingly prompt and dramatic result, these OTC products were further studied in the next nine consecutive patients who were over 50 years old and with presumptive diagnosis of COVID-19.
- RA room air
- ARDS Acute respiratory distress syndrome
- ARDS was defined as bilateral pulmonary opacities on chest radiograph, arterial hypoxemia (partial pressure of arterial oxygen [Pa02] to fraction of inspired oxygen [Fi0 2 ] ratio ⁇ 300), and exclusion of cardiac failure - at time of treatment (See, Bernard etal. The American-European Consensus Conference on ARDS. Am J Respir Crit Care Med. 1994; 149: 818-824).
- FIG. 2 Eight patients (FIG. 2) had positive PCR-based diagnosis from nasal swabs for SARS-CoV-2, Patient 3 had classic Covid-19 clinic presentation (cough, daily fevers to 102°F, severe fatigue and anosmia) and Patient 9 was ruled out for COVID- 19 based on three negative PCR-based nasal swabs for SARS-CoV-2, one negative serologic test for antibodies directed against the virus (day 18 post symptom onset) together with a normal chest x-ray and chest computerized tomography (CT) scan.
- CT computerized tomography
- the nine Covid-19 infected patients were on average 65 years old with frequent co morbidities -two with diabetes, five with pre-diabetes, two with known significant Coronary Artery Disease (CAD), three on baseline meds for Hypertension (HTN), and six with body mass index (BMI) in the overweight category.
- CAD Coronary Artery Disease
- HTN three on baseline meds for Hypertension
- BMI body mass index
- Patient 1 previously were administered hydroxychloroquine plus Zithromax and zinc.
- Patient 10 took a six-day course of hydroxychloroquine.
- Patient 4 received an experimental course of convalescent plasma.
- Chest x-ray improvement was noted in every patient with pneumonia at the onset of treatment (six out of six patients), specifically those with worsening bilateral pulmonary infiltrates (Patients 1, 4, 7 and 10) and bilateral pulmonary infiltrates of unknown onset (Patients 5 and 8) with significant improvement at the first follow-up film (4, 4, 10, 17, 10 and 9 days respectively).
- oral administration of a composition of the present disclosure which included nicotinamide mononucleotide/betaine/Zinc Sulfate (with NaCl to aid absorption), possesses important immune “anti-aging” properties vital in reversing cytokine storm associated with COVID-19.
- Patient 1 A 55-year-old white female presented with a one-day history of body aches, choking cough and fever to 100.2°F. The SARS-CoV-2 PCR test was positive.
- her fever increased to 102.5° F. She was prescribed Zithromax, hydroxychloroquine and zinc sulfate.
- her temp increased to 103° F, she had debilitating body aches, dyspnea at rest, a RA O2 % sat of 90 and chest x-ray with bilateral patchy infiltrates throughout both lungs (FIG. 6) consistent with new onset acute respiratory distress syndrome (ARDS).
- ARDS new onset acute respiratory distress syndrome
- her body mass index was 30 and her history was positive for a recent uneventful elective arm plastic surgery and a past history of episodic hives and allergic reactions to Ivermectin and Keflex.
- Admission labs suggested poor prognosis (CRP (217 mg/L), 11-6 (56 pg/mL), TNF-alpha (7.4 ng/mL) and myoglobin (>500 ng/mL) with absolute lymphopenia (490 cells/pL)).
- CRP prognosis
- 11-6 56 pg/mL
- TNF-alpha 7.4 ng/mL
- myoglobin >500 ng/mL
- absolute lymphopenia 490 cells/pL
- Tocilizumab - a humanized monoclonal antibody that inhibits ligand binding to the human interleukin-6 receptor (IL-6R) - was requested for presumptive cytokine storm, however, strict hospital protocol prohibited the use of this intravenous drug outside of the ICU - and because her O2 % sat on high flow nasal O2 was still > 90, she did not meet criteria for ICU transfer. She therefore agreed to continue Zinc Sulfate and begin NMN, Betaine, Sodium Chloride and zinc (the NMN cocktail) twice a day diluted in 500cc water and timed in sync with the her presumed diurnal circadian rhythm peaks. (Table 4).
- her absolute lymphocyte count increased by 85%. Then, after two weeks of continuous fever, the patient turned afebrile at 5 am on day 14, 36 hours after the NMN cocktail was begun. On day 17 she was discharged home on oral NMN, betaine, NaCl and Zinc Sulfate twice a day; her clinical signs (fever, shortness of breath, body aches) were remarkably better, her room air % O2 sat (up from 84 to 96) and chest x-ray (FIG. 8) also dramatically improved over just 4 days, and showing improved interstitial and alveolar opacities compared with the chest x-ray of day 13. Her laboratory markers (CRP and IL6) simultaneously dropped approximately 80% during the 5 days of in hospital NMN cocktail administration.
- Her third day home she felt stronger and walked multiple times a day.
- Her nasopharyngeal SARS-CoV-2 test was negative.
- Her CRP and IL-6 decreased to 7.4 and 3.2 respectively.
- Her CXR revealed a small amount of residual peripheral infiltrates (FIG. 9) but had dramatically improved interstitial and alveolar opacities
- FIG. 10 lists Patient l’s medical history over the course the study.
- Patient 2 A 60-year-old SARS-CoV-2 NAA positive man with cough, chest tightness, dyspnea, diarrhea and HA was prescribed HCQ, AZ and Zn as an outpatient on his 15th consecutive day of fever. At the completion of the 6-day course he became afebrile and his chest pressure and headache improved, however his cough and insomnia continued. Three days later, his fever, HA and chest pressure recurred. He was begun on the NMN cocktail and experienced a prompt response:
- FIG. 11 lists Patient 2’s medical history over the course the study.
- Patient 3 A 72-year-old woman complained of fever, fatigue, sore throat, cough, HA, anosmia and diarrhea approximately 5 days after her personal assistant came down with a similar constellation of symptoms. She was clinically diagnosed as SARS-COV-2 infected. On symptom day 3, she was seen at her home and begun on HCQ, AZ and Zn. However, despite the “triple therapy” course, her 02 sat dropped from 96 to 94% and her symptoms intensified. She was then treated with the NMN cocktail. She experienced a prompt response: Her 15-day fever resolved within 2 days. Her clinical condition improved in 3 days (resolution of cough, fatigue, and headache).
- FIG. 12 lists Patient 3’s medical history over the course the study.
- Patient 4 A 79-year-old businessman was admitted to the intensive care unit (ICU) on symptom day 22 with ARDS, renal failure (Cr 4.6), diabetes, liver failure (AST/ALT 2878/1598) with possible pulmonary embolism and myocarditis. His chest x-ray on day 22 showed bilateral infiltrates consistent with ARDS (FIG. 13)
- the family requested a second opinion consultation.
- a nasal PCR test was conducted which revealed no virus, making cytokine storm the likely cause of his week- long post convalescent plasma deterioration and rendering the Remdesivir recommendation moot.
- FIG. 17 lists Patient 4’s medical history over the course the study.
- Patient 5 A 52-year female chef (known SARS-CoV-2 NAA positive) was first seen on symptom day 10 complaining of persistent fever, shortness of breath, headache and loss of smell and taste. Her presenting chest x-ray revealed bilateral pneumonia (FIG. 18, showing irregular marginated parenchymal opacities in the R mid and lower lobes and possibly in the left retrocardiac region).
- FIG. 20 lists Patient 5’s medical history over the course the study.
- Patient 6 A 78-year-old Latino man, regularly employed in a physically demanding job, presented after prolonged contact with known SARS-COV-2 NAA positive family members and 5 days after the onset of suspicious symptoms (new fever, cough, sore throat and diarrhea). He was a past smoker on medication for hypertension, coronary heart disease and diabetes type 2. His CXR was normal (FIG. 21).
- Patient 7 A 61 -year-old female first presented to a local ER on symptom day 5 for fever, shortness of breath (SOB), muscle cramps, cough, nausea and diarrhea. Chest x-ray (FIG. 24) was normal but a CT chest revealed several patchy peripheral regions of ground glass opacification bilaterally suspicious for viral pneumonia. She tested positive for SARS- COV-2 RT-PCR and was discharged home with no treatment.
- Patient 8 A 60-year-old cab driver was first seen on symptom day 12 complaining of 10 days of fever, fatigue, and cough and chest pressure. A chest x-ray revealed irregular marginated bilateral parenchymal opacities L>R consistent with bilateral viral pneumonia (FIG. 29). His nasopharynx SARS-COV-2 NAA test returned positive the following day (FIG. 30).
- Patient 10 A 62-year-old SARS-CoV-2 RT-PCR positive businessman was admitted to an outlying hospital on symptom day 14 for spiking fever to 104° F, dropping O2 sats and bilateral pneumonia. His admission chest x-ray (FIG. 32) showed scattered infiltrates predominately within the periphery of bilateral lung fields. On the second day of his hospitalization, he was told there was no treatment for his condition. His interactions with hospital staff doctor and nursing staff was less than a collective 5-10 minutes per day and his wife was not allowed in the hospital or able to speak with the assigned doctor. He requested admission to the hospital but the “lateral” Covid-19 positive patient transfer was denied based on hospital protocol. He then left the hospital against medical advice.
- FIG. 36 lists Patient 10’s medical history over the course the study.
- Example 2 Illustrative formulations for treating at least “Cytokine Storm Syndrome” associated with a viral infection, including COVID-19
- compositions for treating a viral infection are disclosed.
- NMN cocktail examples include Nicotinamide mononucleotide (NMN), Betaine, and Zinc Sulfate in a ratio of from about 7 and 20: to from about 4 and 10; to about 1. Certain formulations further comprise about a ratio of NaCl (to the other components) of from about 0.25 and about 1.25. Sodium helps absorption of components of the compositions.
- NMN cocktail have a unit dose of the composition comprises from about 0.8 grams and about 2.0 grams of NMN, from about 0.4 grams and 0.8 grams of Betaine, and from about 0.09 and 0.25 grams of Zinc Sulfate.
- a unit dose of the composition comprises from about 0.9 grams and about 1.1 grams of NMN, from about 0.45 grams and 0.55 grams of Betaine, and from about 0.1 and 0.12 grams of Zinc Sulfate.
- the unit dose of the composition comprises about 1 gram of NMN, 0.5 grams of Betaine, and about 0.11 grams of Zinc Sulfate.
- the unit dose further may further comprise from about 25 mg to about 100 mg of NaCl. In embodiments, the unit dose further comprises about 50 mg of NaCl.
- a formulation may further comprise additional components that contribute to color, stability, flavor, sweetness, and/or stability.
- At least one unit of compositions of these formulations are administered to a subject at each dosing.
- the subject thus administered may have a viral infection, e.g., caused by the SARS-CoV-2.
- at least two units of the composition, at least three units of the composition, at least four units of the composition, or at least five units of the composition is administered to the subject at each dosing.
- the number of units of the composition per dosing may relate in part to the weight of the subject. For example, when a subject weighs 100 lbs or less, the subject is administered at least one unit of the composition per dosing. When a subject weighs over 100 lbs, the subject is administered at least one unit, at least two units, at least three units, or at least four units or at least five units of the composition per dosing.
- the subject receives at least one dosing per day, at least two dosings per day, at least three dosings per day, or at least four dosings per day.
- compositions may be obtained by a subject or by a healthcare provider in powdered form.
- the powder can be mixed with water or another suitable liquid.
- a unit dose of the composition may be sufficiently soluble in at least about 100 ml of water. If solubility or preference is otherwise, more water/liquid may be mixed. Or less water if at the subject’s preference.
- compositions may be obtained by the subject or the healthcare provider in a sealed air proof, waterproof package, i.e., sachet.
- the sachet may have an inner lining to help protect the composition.
- the sachet may have a tear line, so composition does not spill when the sachet’s top is opened.
- the sachet may have printed instructions on one surface. Illustrative instructions may include: “Take as directed by a physician Dissolve the contents of each sachet completely in a minimum of 100 ml of pure water. Dose in proportion to your body weight. Take on an empty stomach in the morning and/or evening 12 hours apart. Store any unused liquid portion in refrigerator if possible. Freeze unused sachets for long term storage.” Multiple (10 or more) sachets may come in a kit.
- a 61 -year-old Caucasian male weighing 88 kg at the beginning of the treatment was treated with a regimen of an NMN cocktail comprising category 1, category 2, and category 3 molecules as noted below.
- Solutions of various compounds were produced for administering to the subject by mixing a set number of grams with 500 mL of water.
- Typical final concentrations of NMN taken by subject were 3.5 grams in 500 mL H2O, betaine were 3 grams in 500 mL H2O, H2O2 were (2 drops of 35% concentration in 500 mL H2O), and NaSH were (drops of 2 at 66uM per drop concentration in 500 mL H2O).
- each composition was set so that by the subject drinking the full 500 mL a final dosage approximately 1.19 x 10 4 moles NMN/ kg body weight per dose, 2.91 x 10 4 moles betaine / kg body weight per dose, 1.17 x 10 5 moles of H2O2 / kg of body weight per dose, and 1.51 x 10 6 moles of NaSH / kg of body weight per dose was given to the subject through drinking the 500 mL solution.
- Nicotinamide Mononucleotide (NMN) dosage 2.38 x 10 4 moles / Kg body weight / day
- the subject was weighed each day.
- the subject self-administered the formulations orally through drinking the solution at approximately 7AM and 7 PM each day. These times were chosen because they approximated the subjects’ biological clock peaks of NAD+ as determined by Ramsey K 2009. This had the effect of pulsing the ingredients into the body twice a day, approximately timed with the biological clock of the subject.
- LabCor Inc. performed the marker testing using standard protocols on a monthly basis. Blood draw times ranged between 8:19 am and 8:54 am. Inflammatory measurements are correlated to the biological clock. LabCor tested levels of CMV IgG, C-Reactive Protein, Tumor Necrosis Factor-Alpha, and Interleukin-6 in Serum.
- the subject also had the following data collected monthly at LabCorp, including Serum Glucose, Serum Uric Acid, BUN, Serum Creatinine, eGRF if non-African American, BUN/Creatinine Ratio, Serum Sodium, Serum Potassium, Serum Chloride, Total Carbon Dioxide, Serum Calcium, Serum Phosphorus, Serum Total Protein, Serum Albumin, Serum, Total Globulin, A/G Ratio, Total Bilirubin, Serum Alkaline Phosphatase, LDH, AST (SGOT), ALT (SGPT), Serum Iron, Total Cholesterol, Triglycerides, HDL Cholesterol, Calculation VLDL cholesterol Calculation LDL Cholesterol, Total Cholesterol/ HDL ratio, Estimated CHD risk, White Blood Cells, Red Blood Cells, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelets, Neutrophils, Lymph
- Spectral 3 tesla MRI of right calf leg muscle before, during, and after exercise b. Spectral 3 tesla MRI of Liver c. Structural 3 tesla MRI of Liver d. Spectral 3 tesla MRI of Brain (front and back) e. A structural 3 tesla MRI of Brain f. A structural 3 tesla MRI of the right knee (showing Arthritis) g. 3-Nitrotyrosine (a marker for oxidative / nitrative stress) h. Coagulation Tests (a marker for oxidative stress) i.
- F2-isoprostanes (a marker for oxidative / nitrative stress,) j .
- GSH GSSH (a marker for and protection from oxidative / nitrative stress)
- k Urine Organic Acids
- 8-OHDG 8-hydroxy deooxyguanosine
- m Malondialdehyde (a marker for oxidative / nitrative stress)
- hsCRP a marker that can be adversely affected by oxidative stress
- Proteomic profile (a marker for oxidative / nitrative stress)
- a list of medical history questions were answered.
- Body fat and mineral testing was performed at private MD’s office.
- Treadmill testing was performed at private MD’s office.
- 4 tissue biopsy types liver (needle biopsy), skin; adipose, muscle) were obtained (stored at -80 C at UCLA).
- a log of daily exercise and weight was obtained. Also weekly glucose monitoring before and after NMN and BP monitoring before and after NMN was obtained.
- Table 1 The results of the monthly administration schedule and testing for the subject are presented in Table 1.
- Table 1 shows that the subject was provided a formulation on a monthly basis, where the formulation included NMN alone for 3 months, NMN+ betaine for one month, NMN+ betaine + H2O2 for one month and NMN+ betaine +NaSH for one month.
- the age of 61 correlates to the age of unrelated and offspring families in the Arai Y 2015 study detailed herein.
- the markers of the 61 -year-old subject were brought to levels better than the “offspring” group of Arai (CRP, 0.43 mg/1 and IL-6, less than 0.7 pg/mL). While both of these markers do rise slightly in month one, the overall effect of the NMN treatment is to reduce the levels of these markers.
- the lower or approximately similar levels to the “offspring” group of Arai continued to be produced by administration of NMN through months 3, but the effect seemingly plateaus in the 61-year- old male.
- Example 4 Fifty patients have been administered NMN cocktails To date fifty patients have been administered NMN cocktails. In each case, improvements in the patient’s conditions and/or symptoms were observed. A list of the patients treated is included in Table 2, below.
- Example 5 Additional viral infections treated by NMN cocktails
- Illustrative viral infections may be caused by one or more of enteroviruses A-J; rhinoviruses A-C; rotaviruses A-C; norovirus; influenza virus A-C and their several types like H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, H10N7, H7N9, and their other relatives; human papillomaviruses (HPV); polyomaviruses like John Cunningham virus (JCV) and Merkel cell virus (MCV); poxviruses; herpesviruses such as human simplex virus 1 (HSV-1), human simplex virus 2 (HSV-2), varicella zoster virus, Epstein-Barr vims (human herpesvirus 4; EBV/HHV-4), human cytomegalovirus (HHV-5), and Herpesvirus 6 (A&B), herpesvirus 7, Kaposi's sarcoma-associated herpes
- Non-cancer diseases include (i) non-cancer diseases: enteritis (enteroviruses A-J); common cold (rhinoviruses A-C); gastroenteritis, diarrhoea (rotaviruses A-E, norovirus); gastroenteritis (norovirus); influenza (influenza virus A-C); progressive multifocal leukoencephalopathy (JCV), nephrophathy, Merkel cell cancer (MCV), smallpox (variola) (poxvirus); herpes (HSV-1, HSV-2); chicken-pox, herpes zoster (shingles) (varicella zoster virus); infectious mononucleosis (HHV-4); hepatitis A (hepatitis A virus); hepatitis B (hepatitis B virus); hepatitis C (hepatitis C virus); acquired immunodeficiency syndrome (HIV-1, HIV-2, and their subtypes); severe acute respiratory infections
- a subject having or suspected of having a viral infection - other than caused by SARS-CoV-2 - is administered a compound, composition, or formulation as disclosed herein and according to the methods disclosed here; thereby treating or reducing a symptom of the viral infection.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Sont divulgués ici des procédés et des compositions de réduction de l'inflammation, d'inversion du vieillissement et des dégâts cellulaires cumulés, et de traitement, de prévention ou de réduction des effets pathologiques d'une infection virale en particulier celle du SARS-CoV-2, les compositions comprenant un activateur du système de réparation comprenant un nicotinamide mononucléotide, un nicotinamide adénine dinucléotide, un nicotinamide riboside, du 1-méthylnicotinamide et/ou de l'adénosine monophosphate cyclique, un donneur de méthyle comprenant de la bétaïne, du S-5'-adénosyl-L-méthionine, de la méthionine, de la choline, de la séine, du folate et/ou de la vitamine B12, et un activateur de défense antioxydant comprenant du zinc, H2O2, H2S, NaSH, Na2S, du ptérostilbène et/ou du resvératrol.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063004449P | 2020-04-02 | 2020-04-02 | |
US63/004,449 | 2020-04-02 | ||
US202063005145P | 2020-04-03 | 2020-04-03 | |
US63/005,145 | 2020-04-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021202245A1 true WO2021202245A1 (fr) | 2021-10-07 |
Family
ID=77929393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/024207 WO2021202245A1 (fr) | 2020-04-02 | 2021-03-25 | Régimes de traitement antiviral |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021202245A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210322469A1 (en) * | 2020-04-20 | 2021-10-21 | Regents Of The University Of Minnesota | Zinc and copper for the prophylaxis and treatment of covid-19 |
CN114452271A (zh) * | 2022-01-29 | 2022-05-10 | 中国医学科学院药用植物研究所 | 一种二芳基丁烷类化合物在制备抑制新冠病毒的药物中的应用 |
WO2022112806A3 (fr) * | 2020-09-11 | 2022-09-01 | Gyulai Laszlo | Complément alimentaire ou composition médicinale ou pharmaceutique inhibant une infection par virus, avantageusement une infection par coronavirus sras-cov-2 et ibv et formulation associée |
WO2024125113A1 (fr) * | 2022-12-13 | 2024-06-20 | 泓博元生命科技(深圳)有限公司 | Composition pour la prévention et le traitement de l'orage cytokinique |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492421B1 (en) * | 2013-11-14 | 2016-11-15 | Argent Development Group, Llc | Nutritional supplements for treatment of iron deficiency anemia |
US9629846B1 (en) * | 2013-11-14 | 2017-04-25 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
US20170316487A1 (en) * | 2008-04-07 | 2017-11-02 | Mohammad A. Mazed | Optical biomodule for detection of diseases at an early onset |
CN108651993A (zh) * | 2018-08-01 | 2018-10-16 | 泓博元生命科技(深圳)有限公司 | 一种男性保健组合物、制剂及其制备方法与应用 |
CN109045059A (zh) * | 2018-08-01 | 2018-12-21 | 泓博元生命科技(深圳)有限公司 | 一种抗衰老、提高男性精力的组合物、制剂及其制备方法与应用 |
US20190060336A1 (en) * | 2015-10-07 | 2019-02-28 | Joel HUIZENGA | Resetting biological pathways for defending against and repairing deterioration from human aging |
CN112206237A (zh) * | 2019-07-10 | 2021-01-12 | 杨维稼 | 一种含有牛磺酸锌的抗衰老组合物、制备方法及其应用 |
-
2021
- 2021-03-25 WO PCT/US2021/024207 patent/WO2021202245A1/fr active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170316487A1 (en) * | 2008-04-07 | 2017-11-02 | Mohammad A. Mazed | Optical biomodule for detection of diseases at an early onset |
US9492421B1 (en) * | 2013-11-14 | 2016-11-15 | Argent Development Group, Llc | Nutritional supplements for treatment of iron deficiency anemia |
US9629846B1 (en) * | 2013-11-14 | 2017-04-25 | Argent Development Group, Llc | Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women |
US20190060336A1 (en) * | 2015-10-07 | 2019-02-28 | Joel HUIZENGA | Resetting biological pathways for defending against and repairing deterioration from human aging |
CN108651993A (zh) * | 2018-08-01 | 2018-10-16 | 泓博元生命科技(深圳)有限公司 | 一种男性保健组合物、制剂及其制备方法与应用 |
CN109045059A (zh) * | 2018-08-01 | 2018-12-21 | 泓博元生命科技(深圳)有限公司 | 一种抗衰老、提高男性精力的组合物、制剂及其制备方法与应用 |
CN112206237A (zh) * | 2019-07-10 | 2021-01-12 | 杨维稼 | 一种含有牛磺酸锌的抗衰老组合物、制备方法及其应用 |
Non-Patent Citations (4)
Title |
---|
DATABASE GNPD February 2001 (2001-02-01), MINTEL: "Caddy BarTM, specialty chocolate bar", XP055925412, retrieved from GNPD Database accession no. 10082139 * |
HUIZENGA, R.: ": Dramatic clinical improvement in nine consecutive acutely ill elderly COVID-19 patients treated with a nicotinamide mononucleotide cocktail: A retrospective case series", SSRN, 17 August 2020 (2020-08-17), pages 1 - 33, XP055800087, Retrieved from the Internet <URL:https://ssm.eom/abstract-3677428> [retrieved on 20210519] * |
HUIZENGA, R.: "Dramatic Cytokine Storm Reversal with an Over the Counter NMN Cocktail", SSRN, 20 April 2020 (2020-04-20), pages 1 - 11, XP055925197, Retrieved from the Internet <URL:https://ssm.com/abstract=3581388> [retrieved on 20210519] * |
READ, S.A. ET AL.: "The Role of Zinc in Antiviral Immunity", ADVANCES IN NUTRITION, vol. 10, 2019, pages 696 - 710, XP055768698 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210322469A1 (en) * | 2020-04-20 | 2021-10-21 | Regents Of The University Of Minnesota | Zinc and copper for the prophylaxis and treatment of covid-19 |
WO2022112806A3 (fr) * | 2020-09-11 | 2022-09-01 | Gyulai Laszlo | Complément alimentaire ou composition médicinale ou pharmaceutique inhibant une infection par virus, avantageusement une infection par coronavirus sras-cov-2 et ibv et formulation associée |
CN114452271A (zh) * | 2022-01-29 | 2022-05-10 | 中国医学科学院药用植物研究所 | 一种二芳基丁烷类化合物在制备抑制新冠病毒的药物中的应用 |
CN114452271B (zh) * | 2022-01-29 | 2023-03-14 | 中国医学科学院药用植物研究所 | 一种二芳基丁烷类化合物在制备抑制新冠病毒的药物中的应用 |
WO2024125113A1 (fr) * | 2022-12-13 | 2024-06-20 | 泓博元生命科技(深圳)有限公司 | Composition pour la prévention et le traitement de l'orage cytokinique |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021202245A1 (fr) | Régimes de traitement antiviral | |
CA3118834C (fr) | Reinitialisation de voies biologiques de defense contre et de reparation d'une deterioration causee par le vieillissement humain | |
Sagai et al. | Mechanisms of action involved in ozone therapy: is healing induced via a mild oxidative stress? | |
JP7250312B2 (ja) | 筋萎縮性側索硬化症患者の下位集団の治療のためのマシチニブの使用 | |
US6629835B2 (en) | Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2 | |
Greibe et al. | Metformin increases liver accumulation of vitamin B12–an experimental study in rats | |
PT2127652E (pt) | Agente libertador da hormona estimuladora dos folículos | |
BRPI0519471A2 (pt) | formulaÇço complexa de liberaÇço controlada para administraÇço oral de medicamentos para diabÉticos e mÉtodo para o seu preparo | |
BRPI0513673B8 (pt) | método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica | |
Fujimoto et al. | Treatment for crusted scabies: limitations and side effects of treatment with ivermectin | |
Btaiche et al. | Neurologic dysfunction and pancytopenia secondary to acquired copper deficiency following duodenal switch: case report and review of the literature | |
Kayıran et al. | Fluorescence of nails and hair on Wood's lamp examination in Covid pandemic; undefined effect of Favipiravir in humans | |
Neethu et al. | Vitamin C and its therapeutic potential in the management of COVID19 | |
Bryan et al. | Dietary nitrate biochemistry and physiology. An update on clinical benefits and mechanisms of action | |
Heming et al. | Effect of an enteral amino acid blend on muscle and gut functionality in critically ill patients: a proof-of-concept randomized controlled trial | |
US9827222B2 (en) | Treating or preventing nephrogenic diabetes insipidus | |
Rabbani et al. | The treatment of Fasciolopsis buski infection in children: a comparison of thiabendazole, mebendazole, levamisole, pyrantel pamoate, hexylresorcinol and tetrachloroethylene | |
US6369041B2 (en) | Oral combinations of hydroxocobalamin and folic acid | |
DK2374461T3 (en) | Piroxicam for the prophylactic and therapeutic treatment of herpes infections | |
Shorr | Drugs for the Geriatric Patient E-Book: Text with BONUS Handheld Software | |
WO2022228652A1 (fr) | Moyen et méthodes de traitement d'infections virales | |
Tan et al. | Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer | |
US20210401812A1 (en) | Compositions for the prevention and treatment of metabolic syndrome | |
Pelavin et al. | Extended-release glipizide overdose presenting with delayed hypoglycemia and treated with subcutaneous octreotide | |
Goel et al. | Role of L arginine in treatment of osteoporosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21782051 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21782051 Country of ref document: EP Kind code of ref document: A1 |